Advanced & Emerging Topics · Organ CrosstalkMga Makabago at Umuusbong na Paksa · Ugnayan ng mga OrganAbante ug Bag-ong mga Hilisgutan · Ugnayan sa mga OrganBayu at Lulto pang Paksa · Ugnayan da ring Organ

Interorgan Crosstalk in Kidney Health and DiseaseUgnayan ng mga Organ sa Kalusugan at Sakit ng BatoPanag-istoryahanay sa mga Organ sa Kahimsog ug Sakit sa KidneyPamisabi-sabi da ring Organ king Kalusugan at Sakit ning Batu

How your kidneys, heart, lungs, liver, gut, bones, blood, brain and muscles keep each other in balance, and what happens when one of them struggles.Kung paano pinapanatili ng bato, puso, baga, atay, bituka, buto, dugo, utak at kalamnan ang balanse ng isa't isa, at ano ang nangyayari kapag nahirapan ang isa sa kanila.Giunsa pagpabilin sa kidney, kasingkasing, baga, atay, tinai, bukog, dugo, utok ug kaunoran ang balanse sa usag usa, ug unsay mahitabo kung maglisod ang usa kanila.Makananu dang papanatilian ning batu, pusu, baga, ate, bituka, butul, daya, utak at laman ing balanse ning balang metung, at nanu ing malilyari nung masakitan ya ing metung karela.

Summary

Mechanism. The kidneys exchange pressure, hormone, nerve, metabolite and immune signals with the heart, lungs, liver, gut, bone, marrow, brain and muscle. Acute kidney injury (AKI) and chronic kidney disease (CKD) turn these loops into amplifiers.

Evidence. Proof is strongest for shared therapy: empagliflozin reduced kidney disease progression or cardiovascular death (hazard ratio 0.72). Venous Excess Ultrasound (VExUS) grades are associated with AKI in cardiac patients, not in general intensive care. Microbiome and fibroblast growth factor 23 (FGF23) targets remain unproven.

Practice. Read a creatinine rise with congestion, perfusion, urine output and time course. Reassess 3 months after AKI with a urine albumin-to-creatinine ratio (uACR). Pair hemoglobin with iron indices.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 63 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Calm three-dimensional illustration of a pair of kidneys at the center, with a heart, lungs, liver and a length of bone arranged around them on a soft teal background
💡

The one-minute answerAng sagot sa isang minutoAng tubag sa usa ka minutoIng sagot king metung a minutu

Your kidneys do not work alone. All day they trade signals with your heart, lungs, liver, gut, bones, blood-making bone marrow, brain and muscles, through blood flow, hormones, nerves and the substances they clear. When the kidneys are hurt, either suddenly (acute kidney injury, AKI) or slowly over years (chronic kidney disease, CKD), the other organs feel it, and a struggling heart or liver can strain the kidneys in return. This is why your doctor checks more than one organ, and why some treatments protect several organs at once.Hindi nag-iisa ang mga bato (kidney) mo sa trabaho. Buong araw silang nakikipagpalitan ng senyales sa puso, baga, atay, bituka, buto, bone marrow na gumagawa ng dugo, utak at kalamnan, sa pamamagitan ng daloy ng dugo, hormone, nerve at mga sangkap na inaalis nila. Kapag nasaktan ang bato, biglaan man (acute kidney injury, AKI) o dahan-dahan sa loob ng maraming taon (chronic kidney disease, CKD), nadadamay ang ibang organ, at ang nanghihinang puso o atay ay puwede ring magpahirap sa bato. Kaya hindi lang iisang organ ang sinusuri ng doktor mo, at kaya may mga gamot na sabay-sabay na nagpoprotekta sa ilang organ.Dili mag-inusara ang imong mga kidney sa trabaho. Tibuok adlaw silang nagbayloay og senyales sa kasingkasing, baga, atay, tinai, bukog, bone marrow nga naghimo og dugo, utok ug kaunoran, pinaagi sa dagan sa dugo, hormone, nerve ug mga butang nga ilang gitangtang. Kung masamdan ang kidney, kalit man (acute kidney injury, AKI) o hinay-hinay sulod sa daghang tuig (chronic kidney disease, CKD), maapektohan ang ubang organ, ug ang naluyang kasingkasing o atay makapalisod usab sa kidney. Mao nga dili lang usa ka organ ang gisusi sa imong doktor, ug mao nga adunay mga tambal nga dungan nga nanalipod sa pipila ka organ.E la magdili-dili magobra deng batu (kidney) mu. Mabilug a aldo makipagpalitan lang senyales king pusu, baga, ate, bituka, butul, bone marrow a gagawang daya, utak at laman (muscle), kapamilatan ning agus ning daya, hormone, nerve at deng bage a lalakwan da. Nung masaktan ing batu, bigla man (acute kidney injury, AKI) o banayad king lub da ring dakal a banwa (chronic kidney disease, CKD), madamay la ring aliwang organ, at ing manyinang pusu o ate malyari na namang pasakitan ing batu. Anya e mu metung a organ ing susurian ning doktor mu, at anya atin gamut a sabe-sabeng mamrotekta kareng pilan a organ.

⛔

Get urgent care nowMagpatingin agad sa emergencyPagpatan-aw dayon sa emergencyMagpatingin ka agad king emergency

Go to the emergency room if you have kidney disease, or were recently in hospital for a kidney problem, and you notice trouble breathing or breathlessness when lying flat, chest pain, very little or no urine, sudden swelling, confusion or unusual sleepiness, fainting, black or bloody stools, vomiting blood, or a very fast or irregular heartbeat.Pumunta sa emergency room kung may sakit ka sa bato, o kagagaling mo lang sa ospital dahil sa problema sa bato, at napansin mo ang hirap sa paghinga o hingal kapag nakahiga, sakit sa dibdib, napakakaunti o walang ihi, biglaang pamamaga, pagkalito o kakaibang antok, pagkahimatay, maitim o may dugong dumi, pagsusuka ng dugo, o napakabilis o iregular na tibok ng puso.Adto sa emergency room kung aduna kay sakit sa kidney, o bag-o ka lang gikan sa ospital tungod sa problema sa kidney, ug namatikdan nimo ang kalisod sa pagginhawa o hangos kung maghigda, sakit sa dughan, gamay kaayo o walay ihi, kalit nga paghubag, kalibog o dili kasagarang kakatulgon, pagkaluya o pagkawala sa panimuot, itom o dugoon nga hugaw, pagsuka og dugo, o paspas kaayo o dili regular nga pitik sa kasingkasing.Munta ka king emergency room nung atin kang sakit king batu, o bayu ka pa mung menibat king ospital uli ning problema king batu, at apansinan mu ing kasakitan king pangisnawa o pangingal nung makakera, sakit king salu, dipaning ditak o alang imi, biglang pamagbulkas (swelling), pamaglito o e karaniwan a tundu, pamagkahimatay, matuling o maki-dayang takla, pamagmulua daya, o masikan a masikan o e regular a pamitik ning pusu.

Eight pictures of danger signs under a red banner: trouble breathing lying down, chest pain, very little urine, sudden swelling, confusion, fainting, black stool or vomiting blood, and a fast uneven heartbeat

If you have kidney disease and notice any of these signs, go to the emergency room now.Kung may sakit ka sa bato at napansin mo ang alinman sa mga senyales na ito, pumunta agad sa emergency room.Kung aduna kay sakit sa kidney ug namatikdan nimo ang bisan asa niining mga timaan, adto dayon sa emergency room.Nung atin kang sakit king batu at apansinan mu ing nanu man kareting tanda, munta ka agad king emergency room.

Your kidneys are part of a teamBahagi ng isang team ang mga bato moBahin sa usa ka team ang imong mga kidneyKayabe la king metung a team deng batu mu

Think of your body as a barangay where every household depends on its neighbors. The kidneys are the household that manages water, salt and waste for everyone. They also send out instructions: one hormone tells the bone marrow to make red blood cells, another activates vitamin D for the bones, and another helps set blood pressure. In return, the kidneys depend on the heart for steady blood flow, on the lungs for oxygen, and on the liver and gut to handle food and medicines.Isipin ang katawan mo na parang isang barangay kung saan umaasa ang bawat bahay sa mga kapitbahay. Ang mga bato ang bahay na namamahala sa tubig, asin at dumi para sa lahat. Nagpapadala rin sila ng utos: isang hormone ang nagsasabi sa bone marrow na gumawa ng pulang selula ng dugo, isa ang nagpapagana ng vitamin D para sa buto, at isa pa ang tumutulong magtakda ng presyon ng dugo. Bilang kapalit, umaasa ang bato sa puso para sa tuloy-tuloy na daloy ng dugo, sa baga para sa oxygen, at sa atay at bituka para asikasuhin ang pagkain at gamot.Hunahunaa ang imong lawas sama sa usa ka barangay diin ang matag balay nagsalig sa mga silingan. Ang mga kidney mao ang balay nga nagdumala sa tubig, asin ug hugaw para sa tanan. Nagpadala usab sila og mga sugo: usa ka hormone ang nagsulti sa bone marrow nga maghimo og pulang selula sa dugo, lain ang nagpaaktibo sa vitamin D para sa bukog, ug lain pa ang nagtabang sa pagtakda sa presyon sa dugo. Isip balos, nagsalig ang kidney sa kasingkasing para sa makanunayong dagan sa dugo, sa baga para sa oxygen, ug sa atay ug tinai aron atimanon ang pagkaon ug tambal.Isipan me ing katawan mu antimong metung a barangay nung nu ing balang bale manasa ya kareng kasiping bale na. Deng batu ilang bale a mamanibala king danum, asin at dinat para kareng ngan. Magpadala la namang utus: metung a hormone ing sasabi king bone marrow a gumawa yang malutung selula ning daya, metung ing magpagana king vitamin D para king butul, at metung pa ing sasaup king presyon ning daya. Kapalit na niti, manasa ya ing batu king pusu para king tuluy-tuluy a agus ning daya, king baga para king oxygen, at king ate at bituka ban asikasuan ing pamangan at gamut.

Two matching panels: a neighborhood of five houses around a water pump linked by footpaths, and the heart, lungs, liver, bone and kidneys linked by arrows in the same positions

Your organs depend on each other the way neighbors do. When one struggles, the others feel it.Umaasa ang mga organ mo sa isa't isa gaya ng magkakapitbahay. Kapag nahirapan ang isa, nadarama ito ng iba.Ang imong mga organ nagsalig sa usag usa sama sa mga silingan. Kung maglisod ang usa, mabati kini sa uban.Deng organ mu manasa la king balang metung antimo reng mikakasiping bale. Nung masakitan ya ing metung, aramdaman da reng aliwa.

In real terms, organs talk in five ways: by pressure and blood flow, by hormones carried in the blood, by nerve signals, by the substances they make or clear, and by the immune system. A problem in one channel can travel. Too much fluid backs up into the lungs. Waste the kidneys cannot clear reaches the brain. A weak heart pump lowers the flow the kidneys need to filter.Sa totoong katawan, limang paraan ang pag-uusap ng mga organ: sa presyon at daloy ng dugo, sa mga hormone na dala ng dugo, sa senyales ng nerve, sa mga sangkap na ginagawa o inaalis nila, at sa immune system. Ang problema sa isang daanan ay puwedeng kumalat. Ang sobrang tubig ay umaatras papunta sa baga. Ang duming hindi maalis ng bato ay umaabot sa utak. Ang mahinang bomba ng puso ay nagpapababa ng daloy na kailangan ng bato para makapagsala.Sa tinuod nga lawas, lima ka paagi ang pag-istoryahanay sa mga organ: pinaagi sa presyon ug dagan sa dugo, sa mga hormone nga dala sa dugo, sa senyales sa nerve, sa mga butang nga ilang gihimo o gitangtang, ug sa immune system. Ang problema sa usa ka agianan mahimong mokaylap. Ang sobrang tubig moatras ngadto sa baga. Ang hugaw nga dili matangtang sa kidney moabot sa utok. Ang huyang nga bomba sa kasingkasing makapaubos sa dagan nga gikinahanglan sa kidney aron makasala.King tutung katawan, lima lang paralan ing pamisabi-sabi da ring organ: king presyon at agus ning daya, kareng hormone a dadalan ning daya, king senyales ning nerve, kareng bage a gagawan o lalakwan da, at king immune system. Ing problema king metung a dalan malyari yang kumalat. Ing sobrang danum mamalik ya papunta king baga. Ing dinat a e na alako ning batu miraras ya king utak. Ing manyinang bomba ning pusu papababan ne ing agus a kailangan ning batu ban makapagsala.

Line-art diagram with a pair of kidneys at the center, linked by dotted two-way arrows to a heart, lungs, liver, intestine, bone, blood cells, brain and muscle arranged in a ring

The kidneys sit at the center of a two-way network. Every arrow runs in both directions: each organ affects the kidneys, and the kidneys affect each organ.Nasa gitna ng dalawahang-direksyong network ang mga bato. Bawat arrow ay pabalik-balik: bawat organ ay nakaaapekto sa bato, at ang bato ay nakaaapekto sa bawat organ.Ang mga kidney anaa sa tunga sa network nga duha ang direksyon. Ang matag arrow balik-balik: ang matag organ makaapekto sa kidney, ug ang kidney makaapekto sa matag organ.Deng batu atyu la king libutad ning network a adwa ing direksyon. Ing balang arrow papunta at pabalik: ing balang organ makaapektu ya king batu, at ing batu makaapektu ya king balang organ.

Why did my kidneys get worse when my heart was sick?Bakit lumala ang bato ko noong nagkasakit ang puso ko?Nganong migrabe ang akong kidney sa dihang nasakit ang akong kasingkasing?Bakit lumala ya ing batu ku inyang mesakit ya ing pusu ku?

I first met her when her husband started dialysis. He had lived with high blood pressure that was hard to control, and he later developed diabetes and heart disease. After he died, she became my patient. She was living with diabetes and high blood pressure, and she had gained weight.Una ko siyang nakilala noong nagsimulang mag-dialysis ang kanyang asawa. Matagal itong nagkaroon ng mataas na presyon na mahirap kontrolin, at kalaunan ay nagkaroon din ito ng diabetes at sakit sa puso. Nang pumanaw ito, siya naman ang naging pasyente ko. May diabetes at mataas na presyon siya, at tumaba siya.Una nako siyang nahimamat sa dihang nagsugod og dialysis ang iyang bana. Dugay na kining may taas nga presyon nga lisod kontrolon, ug sa kadugayan naangkon usab niini ang diabetes ug sakit sa kasingkasing. Human kini namatay, siya na ang nahimong akong pasyente. Aduna siyay diabetes ug taas nga presyon, ug nitambok siya.Mumuna ke pengakilala inyang megumpisa yang mag-dialysis ing asawa na. Malambat neng atin matas a presyon a masakit kontrolan, at kaibat miyabe pa ing diabetes at sakit king pusu. Inyang mete ya, iya naman ing meging pasyenti ku. Atin yang diabetes at matas a presyon, at tinaba ya.

When she started getting short of breath, I looked more closely at her heart. Her blood pressure could run very high and then drop low. The evaluation found heart disease, and I referred her to cardiology. During one severe episode of breathlessness, she needed intensive care and a breathing tube. Over time, her creatinine, a blood test we use to check kidney function, rose. She eventually developed stage 4 chronic kidney disease. After discussing heart surgery with her specialists, she chose to continue with medical treatment.Nang magsimula siyang hingalin, mas sinuri ko nang mabuti ang kanyang puso. Ang presyon niya ay puwedeng tumaas nang husto at pagkatapos ay bumaba nang mababa. Nakita sa pagsusuri na may sakit siya sa puso, kaya ini-refer ko siya sa cardiology. Sa isang malubhang atake ng hingal, kinailangan niya ng intensive care at ng tubo para sa paghinga. Sa paglipas ng panahon, tumaas ang kanyang creatinine, isang blood test na ginagamit namin para tingnan ang lagay ng bato. Kalaunan ay umabot siya sa stage 4 chronic kidney disease. Matapos pag-usapan ang operasyon sa puso kasama ang kanyang mga espesyalista, pinili niyang ipagpatuloy ang gamutan sa pamamagitan ng mga gamot.Sa dihang nagsugod siya og hangos, gisusi nako pag-ayo ang iyang kasingkasing. Ang iyang presyon mahimong mosaka pag-ayo ug unya moubos. Nakita sa pagsusi nga aduna siyay sakit sa kasingkasing, busa gi-refer nako siya sa cardiology. Sa usa ka grabeng higayon sa hangos, nagkinahanglan siya og intensive care ug tubo alang sa pagginhawa. Sa paglabay sa panahon, misaka ang iyang creatinine, usa ka blood test nga among gigamit sa pagsusi sa kidney. Sa kadugayan, miabot siya sa stage 4 chronic kidney disease. Human mahisgoti ang operasyon sa kasingkasing uban sa iyang mga espesyalista, gipili niya nga ipadayon ang pagtambal pinaagi sa mga tambal.Inyang megumpisa yang hingalan, sinuri ke pang masalese ing pusu na. Ing presyon na malyari yang tumas masyadu at kaibat magbaba yang mababa. Ikit king pamanyuri a atin yang sakit king pusu, anya ni-refer ke king cardiology. King metung a malalang atake ning hingal, kinailangan na ing intensive care at tubo para king pamangisnawa. Kabang lalabas ing panaun, tinas ya ing creatinine na, metung a blood test a gagamitan mi para lawen ing lagay ning batu. Kaibat, miras ya king stage 4 chronic kidney disease. Kaibat dang pisabyan ing operasyon king pusu kayabe da reng espesyalista na, pinili nang isundu ing pamanulu kapamilatan da reng gamut.

Years later, she asked me how a problem in her heart could affect her kidneys.Makalipas ang ilang taon, tinanong niya ako kung paano nakaaapekto sa kanyang bato ang problema sa kanyang puso.Paglabay sa pipila ka tuig, gipangutana ko niya kung giunsa pag-apektar sa problema sa iyang kasingkasing ang iyang kidney.Kaibat ning pilan a banwa, kitnan na ku nung makananu yang makaapektu king batu na ing problema king pusu na.

I explained that the kidneys need blood to reach them and room for it to drain away. Very low blood pressure can reduce the blood reaching them. Pressure that backs up in the veins can also make it harder for the kidneys to filter. The effect goes both ways. When the kidneys have trouble clearing extra salt and water, the fluid can raise blood pressure and make it harder for the heart to handle that volume. Diabetes and long-standing high blood pressure can damage both organs over time.Ipinaliwanag ko na kailangan ng bato na may dugong dumarating dito at may daan para makalabas ito. Kapag sobrang baba ng presyon, puwedeng mabawasan ang dugong nakararating sa bato. Kapag umaatras naman ang presyon sa mga ugat (veins), mas nahihirapan ding magsala ang bato. Dalawahan ang epekto. Kapag nahihirapan ang bato na ilabas ang sobrang asin at tubig, puwedeng tumaas ang presyon dahil sa naipong tubig at mas mahirapan ang puso na kayanin ang dami nito. Ang diabetes at matagal nang mataas na presyon ay puwedeng makasira sa dalawang organ sa paglipas ng panahon.Gipatin-aw nako nga ang kidney nagkinahanglan og dugo nga moabot niini ug agianan aron makagawas kini. Ang sobra ka ubos nga presyon makapakunhod sa dugo nga moabot sa kidney. Ang presyon nga moatras sa mga ugat (veins) makapalisod usab sa pagsala sa kidney. Duha ka direksyon ang epekto. Kung maglisod ang kidney sa pagpagawas sa sobrang asin ug tubig, ang natigom nga tubig makapataas sa presyon ug makapalisod sa kasingkasing sa pagdala niana nga gidaghanon. Ang diabetes ug dugay na nga taas nga presyon makadaot sa duha ka organ sa paglabay sa panahon.Pepaliwanag ku a kailangan ning batu ing daya a datang kaya at dalan para makalwal ya iti. Nung masyadu yang mababa ing presyon, malyari yang mabawasan ing daya a darasan king batu. Nung aatras ya naman ing presyon kareng uyat (veins), lalu yang masakitan ing batu a magsala. Adwa ing direksyon ning epektu. Nung masakitan ya ing batu a ilwal ing sobrang asin at danum, ing metipun a danum malyari neng patasan ing presyon at lalu yang masakitan ing pusu a dalan ing dakal a ita. Ing diabetes at malambat nang matas a presyon malyari dong siran deng adwang organ kabang lalabas ing panaun.

That is why I look at her breathing, blood pressure, weight, and kidney tests together. When one changes, it helps me know what to check next.Kaya sabay-sabay kong tinitingnan ang kanyang paghinga, presyon, timbang, at mga test sa bato. Kapag may nagbago sa isa, natutulungan akong malaman kung ano ang susunod na dapat suriin.Mao nga dungan nakong tan-awon ang iyang pagginhawa, presyon, timbang, ug mga test sa kidney. Kung adunay mausab sa usa, makatabang kini kanako nga mahibal-an kung unsay sunod nga susihon.Anya misasabe kung lalawen ing pamangisnawa na, presyon, timbang, at deng test king batu. Nung atin mibayu king metung, makasaup ya kanaku para abalu ku nung nanu ing tutuking dapat suriin.

Who talks to the kidneys, and what they saySino ang kausap ng mga bato, at ano ang sinasabi nilaKinsa ang kaistorya sa mga kidney, ug unsay ilang giingonNinu ing kasabi da ring batu, at nanu ing sasabyan da

Each row below is one conversation. Read across to see what each side gives, what goes wrong, and what your care team watches.Bawat hanay sa ibaba ay isang usapan. Basahin pahalang para makita kung ano ang ibinibigay ng bawat panig, ano ang nagkakamali, at ano ang binabantayan ng care team mo.Ang matag laray sa ubos usa ka panag-istoryahanay. Basaha pahigda aron makita kung unsay ihatag sa matag kilid, unsay masayop, ug unsay gibantayan sa imong care team.Ing balang hanay king lalam metung yang pamisabi-sabi. Basan yang pahalang ban akit mu nung nanu ing ibibye ning balang panig, nanu ing mamali, at nanu ing babanten ning care team mu.

Eight cards, each showing a pair of kidneys beside one partner organ with a two-way arrow: heart, lungs, liver, gut, bones, blood, brain and muscles

Each partner organ shares one job with the kidneys. The table below explains each one.Bawat katuwang na organ ay may isang trabahong kasalo ang bato. Ipinapaliwanag ng talahanayan sa ibaba ang bawat isa.Ang matag kauban nga organ adunay usa ka trabaho nga giambitan sa kidney. Ang talaan sa ubos nagpatin-aw sa matag usa.Ing balang kayabeng organ atin yang metung a obrang kayabe na ing batu. Ing talaan king lalam ipaliwanag na ing balang metung.

Partner organKatuwang na organKauban nga organKayabeng organHow they help each otherPaano sila nagtutulunganGiunsa nila pagtinabangayMakananu lang misasaupWhen trouble startsKapag nagkaproblemaKung magsugod ang problemaNung magumpisa ing problema
Heart and blood vesselsPuso at mga ugatKasingkasing ug mga ugatPusu at deng uyatThe heart pumps blood to the kidneys. The kidneys control salt, water and blood pressure for the heart.Nagbobomba ang puso ng dugo papunta sa bato. Kinokontrol ng bato ang asin, tubig at presyon para sa puso.Ang kasingkasing mobomba og dugo ngadto sa kidney. Ang kidney mokontrol sa asin, tubig ug presyon para sa kasingkasing.Ing pusu bobomba yang daya papunta king batu. Ing batu kokontrolan ne ing asin, danum at presyon para king pusu.A weak heart or backed-up veins slow the kidneys. Weak kidneys hold fluid and potassium that strain the heart. Checked: blood pressure, weight, swelling, creatinine, potassium.Ang mahinang puso o naiipong dugo sa ugat ay nagpapabagal sa bato. Ang mahinang bato ay nag-iipon ng tubig at potassium na nagpapahirap sa puso. Sinusuri: presyon, timbang, pamamaga, creatinine, potassium.Ang huyang nga kasingkasing o natigom nga dugo sa ugat makapahinay sa kidney. Ang huyang nga kidney magtigom og tubig ug potassium nga makapalisod sa kasingkasing. Susihon: presyon, timbang, paghubag, creatinine, potassium.Ing manyinang pusu o ing dayang titipun king uyat papabagalan ne ing batu. Ing manyinang batu titipunan ne ing danum at potassium a magpasakit king pusu. Susurian: presyon, timbang, pamagbulkas, creatinine, potassium.
LungsBagaBagaBagaThe lungs remove carbon dioxide, an acid gas. The kidneys remove other acids. Together they keep the blood from becoming too acidic.Inaalis ng baga ang carbon dioxide, isang maasim na gas. Inaalis ng bato ang ibang asido. Magkasama nilang pinipigilang maging sobrang asido ang dugo.Ang baga motangtang sa carbon dioxide, usa ka aslom nga gas. Ang kidney motangtang sa ubang asido. Mag-uban silang nagpugong nga mahimong aslom kaayo ang dugo.Ing baga lalakwan ne ing carbon dioxide, metung a maslam a gas. Ing batu lalakwan ne ing aliwang asidu. Misasabe dang pipigilan a maging sobrang maslam ing daya.Extra fluid from weak kidneys can fill the lungs and cause breathlessness. A severe lung illness lowers the oxygen reaching the kidneys. Checked: breathing, oxygen level, fluid in and out.Ang sobrang tubig dahil sa mahinang bato ay puwedeng pumuno sa baga at magdulot ng hingal. Ang malubhang sakit sa baga ay nagpapababa ng oxygen na umaabot sa bato. Sinusuri: paghinga, antas ng oxygen, tubig na pumapasok at lumalabas.Ang sobrang tubig tungod sa huyang nga kidney mahimong mopuno sa baga ug magpahangos. Ang grabeng sakit sa baga makapaubos sa oxygen nga moabot sa kidney. Susihon: pagginhawa, lebel sa oxygen, tubig nga mosulod ug mogawas.Ing sobrang danum uli ning manyinang batu malyari neng kasnukan ing baga at magpangingal. Ing malalang sakit king baga papababan ne ing oxygen a miraras king batu. Susurian: pangisnawa, lebel ning oxygen, danum a lulub at lulwal.
LiverAtayAtayAteThe liver processes food and medicines. The kidneys clear what is left over.Pinoproseso ng atay ang pagkain at gamot. Inaalis ng bato ang natitira.Ang atay moproseso sa pagkaon ug tambal. Ang kidney motangtang sa nahabilin.Ing ate poprosesuan ne ing pamangan at gamut. Ing batu lalakwan ne ing mitagan.In advanced liver scarring (cirrhosis), blood flow to the kidneys can fall sharply. Checked: creatinine, urine amount, fluid in the belly, infection.Sa malalang pagkakapeklat ng atay (cirrhosis), puwedeng biglang bumaba ang daloy ng dugo sa bato. Sinusuri: creatinine, dami ng ihi, tubig sa tiyan, impeksyon.Sa grabeng pagkauwat sa atay (cirrhosis), mahimong kalit nga moubos ang dagan sa dugo ngadto sa kidney. Susihon: creatinine, gidaghanon sa ihi, tubig sa tiyan, impeksyon.King malalang pamagpilat ning ate (cirrhosis), malyari yang biglang mababa ing agus ning daya king batu. Susurian: creatinine, dakal ning imi, danum king atyan, impeksyon.
GutBitukaTinaiBitukaGut bacteria help digest food. The kidneys clear some of what those bacteria produce.Tumutulong ang bacteria sa bituka sa pagtunaw ng pagkain. Inaalis ng bato ang ilan sa ginagawa ng mga bacteria na iyon.Ang bacteria sa tinai motabang sa pagtunaw sa pagkaon. Ang kidney motangtang sa pipila sa gihimo sa maong bacteria.Deng bacteria king bituka sasaup la king pamaglaso ning pamangan. Ing batu lalakwan ne ing pilan kareng gagawan da reng bacteria.In CKD some of these substances build up in the blood. Constipation and low-fiber eating may add to this. Checked: bowel habits, diet, potassium.Sa CKD, naiipon sa dugo ang ilan sa mga sangkap na ito. Puwedeng makadagdag ang pagtitibi at kulang sa fiber na pagkain. Sinusuri: pagdumi, pagkain, potassium.Sa CKD, ang pipila niining mga butang matigom sa dugo. Ang pagkatubol ug kulang sa fiber nga pagkaon mahimong makadugang niini. Susihon: pagkalibang, pagkaon, potassium.King CKD, deng pilan kareti titipun la king daya. Ing pamagtibi (constipation) at ing pamangan a kulang king fiber malyari lang makadagdag. Susurian: pamanakla, pamangan, potassium.
Bones and parathyroid glandsButo at parathyroid glandBukog ug parathyroid glandButul at parathyroid glandThe kidneys activate vitamin D and balance calcium and phosphate for strong bones.Pinapagana ng bato ang vitamin D at binabalanse ang calcium at phosphate para sa matibay na buto.Ang kidney mopaaktibo sa vitamin D ug mobalanse sa calcium ug phosphate para sa lig-ong bukog.Ing batu pagaganan ne ing vitamin D at babalansian ne ing calcium at phosphate para king masikan a butul.In CKD, phosphate and parathyroid hormone (PTH) rise, bones weaken and blood vessels may stiffen. Checked: calcium, phosphate, PTH.Sa CKD, tumataas ang phosphate at parathyroid hormone (PTH), humihina ang buto at puwedeng tumigas ang mga ugat. Sinusuri: calcium, phosphate, PTH.Sa CKD, motaas ang phosphate ug parathyroid hormone (PTH), moluya ang bukog ug mahimong mogahi ang mga ugat. Susihon: calcium, phosphate, PTH.King CKD, tataas ing phosphate at parathyroid hormone (PTH), manyina ing butul at malyari lang sumyas deng uyat. Susurian: calcium, phosphate, PTH.
Blood and bone marrowDugo at bone marrowDugo ug bone marrowDaya at bone marrowThe kidneys make erythropoietin, the signal that tells the marrow to make red blood cells.Gumagawa ang bato ng erythropoietin, ang senyales na nag-uutos sa marrow na gumawa ng pulang selula ng dugo.Ang kidney maghimo og erythropoietin, ang senyales nga nagsugo sa marrow nga maghimo og pulang selula sa dugo.Ing batu gagawa yang erythropoietin, ing senyales a mag-utus king marrow a gumawa yang malutung selula ning daya.In CKD the signal weakens and iron gets locked in storage, causing anemia: tiredness, pale skin, breathlessness. Checked: hemoglobin and iron tests.Sa CKD, humihina ang senyales at nakukulong ang iron sa imbakan, kaya nagkaka-anemia: pagod, pamumutla, hingal. Sinusuri: hemoglobin at mga test sa iron.Sa CKD, moluya ang senyales ug ang iron masirhan sa tipiganan, hinungdan sa anemia: kakapoy, pagkaluspad, hangos. Susihon: hemoglobin ug mga test sa iron.King CKD, manyina ing senyales at ing iron makakulung ya king imbakan, anya mika-anemia: pagal, pamamutla, pangingal. Susurian: hemoglobin at deng test king iron.
Brain and nervesUtak at mga nerveUtok ug mga nerveUtak at deng nerveNerves from the brain adjust kidney blood flow and how much salt the kidneys keep.Inaayos ng mga nerve mula sa utak ang daloy ng dugo sa bato at kung gaano karaming asin ang iniiwan nito.Ang mga nerve gikan sa utok mo-adjust sa dagan sa dugo sa kidney ug kung pila ka asin ang ipabilin niini.Deng nerve a manibat king utak a-adjust de ing agus ning daya king batu at nung makananu karakal ing asin a itagan na.When wastes build up or sodium shifts, thinking and sleep can suffer. High blood pressure harms both organs. Checked: alertness, blood pressure, sodium.Kapag naipon ang dumi o nagbago ang sodium, puwedeng maapektuhan ang pag-iisip at tulog. Sinisira ng mataas na presyon ang dalawang organ. Sinusuri: pagkaalerto, presyon, sodium.Kung matigom ang hugaw o mausab ang sodium, mahimong maapektohan ang panghunahuna ug katulog. Ang taas nga presyon makadaot sa duha ka organ. Susihon: pagka-alerto, presyon, sodium.Nung matipun ing dinat o magbayu ing sodium, malyari yang maapektuan ing pamag-isip at tundu. Ing matas a presyon sisiran na la ring adwang organ. Susurian: pangaalerto, presyon, sodium.
MusclesKalamnanKaunoranLaman (muscle)Muscles make creatinine, the waste product used to estimate kidney function.Ang kalamnan ang gumagawa ng creatinine, ang duming ginagamit para tantiyahin ang paggana ng bato.Ang kaunoran maghimo og creatinine, ang hugaw nga gigamit aron banabanaon ang paglihok sa kidney.Ing laman gagawa yang creatinine, ing dinat a gagamitan ban tantyan ing pamagobra ning batu.CKD can cause muscle loss, and with less muscle the creatinine can look better than the kidneys really are. Checked: strength, weight, sometimes a cystatin C test.Puwedeng magdulot ang CKD ng pagliit ng kalamnan, at kapag kaunti ang kalamnan, puwedeng magmukhang mas maganda ang creatinine kaysa sa totoong lagay ng bato. Sinusuri: lakas, timbang, minsan ang cystatin C test.Ang CKD mahimong hinungdan sa pagkunhod sa kaunoran, ug kung gamay ang kaunoran, ang creatinine mahimong tan-awon nga mas maayo kaysa sa tinuod nga kahimtang sa kidney. Susihon: kusog, timbang, usahay ang cystatin C test.Ing CKD malyari yang panibatan ning pamaglati ning laman, at nung ditak ing laman, ing creatinine malyari yang lumto mas masanting kesa king tutung lagay ning batu. Susurian: sikan, timbang, neng kayi ing cystatin C test.

Sudden kidney injury and long-term kidney disease are different conversationsMagkaibang usapan ang biglaang pinsala sa bato at pangmatagalang sakit sa batoLahi nga panag-istoryahanay ang kalit nga kadaot sa kidney ug dugay nga sakit sa kidneyMiyaliwa lang pamisabi-sabi ing biglang pinsala king batu at ing makabang sakit king batu

Acute kidney injury happens over hours to days, often during a serious illness such as an infection, dehydration, heart failure or after major surgery. Because the same illness can hurt several organs at once, doctors look at the timing, your blood pressure, how much urine you pass and whether you are swollen or dry before deciding what a rising creatinine means. Two people with the same creatinine can need opposite treatments: one needs fluid removed, the other needs fluid given.Ang acute kidney injury ay nangyayari sa loob ng ilang oras hanggang araw, kadalasan habang may malubhang sakit tulad ng impeksyon, dehydration, heart failure o pagkatapos ng malaking operasyon. Dahil puwedeng sabay-sabay na saktan ng iisang sakit ang ilang organ, tinitingnan ng doktor ang takbo ng oras, presyon mo, dami ng ihi at kung namamaga ka o tuyo bago magpasya kung ano ang ibig sabihin ng tumataas na creatinine. Dalawang taong pareho ang creatinine ay puwedeng mangailangan ng magkasalungat na gamutan: ang isa ay kailangang bawasan ng tubig, ang isa ay kailangang bigyan.Ang acute kidney injury mahitabo sulod sa pipila ka oras hangtod adlaw, kasagaran samtang adunay grabeng sakit sama sa impeksyon, dehydration, heart failure o human sa dakong operasyon. Tungod kay ang usa ka sakit mahimong dungan nga makadaot sa pipila ka organ, tan-awon sa doktor ang panahon, imong presyon, gidaghanon sa ihi ug kung nanghubag ka o uga sa dili pa modesisyon kung unsay kahulogan sa nagsaka nga creatinine. Ang duha ka tawo nga parehas og creatinine mahimong magkinahanglan og sukwahi nga pagtambal: ang usa kinahanglang kuhaan og tubig, ang usa kinahanglang hatagan.Ing acute kidney injury malilyari ya king lub da ring pilan a oras angga king aldo, kalambang kabang atin malalang sakit antimo ing impeksyon, dehydration, heart failure o kaybat ning maragul a operasyon. Uling ing metung a sakit malyari nong sabe-sabeng saktan deng pilan a organ, lalawen ning doktor ing panaun, ing presyon mu, ing dakal ning imi mu at nung mamulkas ka o malangi bayu ya magdesisyon nung nanu ing buri nang sabyan ning tataas a creatinine. Adwang taung pareu ing creatinine malyari lang mangailangan misalungat a pamanulu: ing metung kailangan yang bawasan danum, ing metung kailangan yang dinan.

One laboratory slip reading creatinine up feeds two panels: a man with swollen legs and breathlessness from too much fluid, and a woman who is dizzy and dry from too little fluid

The same rising creatinine can mean too much fluid or too little. The treatment is opposite, so your doctor examines you as well as the number.Ang parehong tumataas na creatinine ay puwedeng mangahulugan ng sobrang tubig o kulang na tubig. Magkasalungat ang gamutan, kaya sinusuri ka ng doktor at hindi lang ang numero.Ang parehas nga nagsaka nga creatinine mahimong magpasabot og sobrang tubig o kulang nga tubig. Sukwahi ang pagtambal, mao nga susihon ka sa doktor ug dili lang ang numero.Ing pareung tataas a creatinine malyari neng buri sabyan sobrang danum o kulang a danum. Misalungat ing pamanulu, anya susurian na ka ning doktor at e mu ing numeru.

Chronic kidney disease develops over months to years. The body adapts, but the adaptations have a cost: higher blood pressure, anemia, changes in bone and minerals, and a higher chance of heart disease. Most of these are found by blood and urine tests long before you feel them.Ang chronic kidney disease ay nabubuo sa loob ng mga buwan hanggang taon. Umaangkop ang katawan, pero may kapalit ang pag-angkop: mas mataas na presyon, anemia, pagbabago sa buto at mineral, at mas mataas na tsansa ng sakit sa puso. Karamihan nito ay nakikita sa test ng dugo at ihi bago mo pa maramdaman.Ang chronic kidney disease motubo sulod sa mga bulan hangtod tuig. Mo-adjust ang lawas, apan adunay bayad ang pag-adjust: mas taas nga presyon, anemia, kausaban sa bukog ug mineral, ug mas taas nga tsansa sa sakit sa kasingkasing. Kadaghanan niini makita sa test sa dugo ug ihi sa wala pa nimo mabati.Ing chronic kidney disease mabubuu ya king lub da ring bulan angga king banwa. Mag-adjust ya ing katawan, pero atin yang kapalit ing pamag-adjust: mas matas a presyon, anemia, pamagbayu king butul at mineral, at mas matas a tsansa ning sakit king pusu. Keraklan kareti akakit la king test ning daya at imi bayu mu pa aramdaman.

Timeline from left to right: a hospital stay with sudden kidney injury, a recovery period, and a flag at three months marked for a kidney check with a blood test and a urine test

After a sudden kidney injury, the first 3 months are a recovery window. A blood test and a urine albumin test at or before the 3-month mark show whether the kidneys have recovered or need continued care.Pagkatapos ng biglaang pinsala sa bato, ang unang 3 buwan ay panahon ng paggaling. Ipinapakita ng test sa dugo at test ng albumin sa ihi sa o bago ang ika-3 buwan kung gumaling na ang bato o kailangan pa ng tuloy-tuloy na pangangalaga.Human sa kalit nga kadaot sa kidney, ang unang 3 ka bulan mao ang panahon sa pagkaayo. Ang test sa dugo ug test sa albumin sa ihi sa o sa dili pa ang ika-3 nga bulan magpakita kung naayo na ang kidney o nagkinahanglan pa og padayong pag-atiman.Kaybat ning biglang pinsala king batu, ing mumunang 3 bulan panaun yang pamagkaulu. Ing test ning daya at test ning albumin king imi king o bayu ing ka-3 bulan papakit na nung mekaulu ne ing batu o kailangan na pa ing tuluy-tuluy a pamag-alaga.

AKI
Acute kidney injury
CKD
Chronic kidney disease
uACR
Urine albumin-to-creatinine ratio
⚠️

After a hospital stay with AKIPagkatapos ma-ospital dahil sa AKIHuman ma-ospital tungod sa AKIKaybat mi-ospital uli ning AKI

A kidney that was injured needs a follow-up check even if you feel well. Ask for a kidney check that includes a urine albumin test within 3 months of the injury, and sooner if you went home on dialysis, have heart failure, or your doctor advised it. People who had AKI are more likely to develop CKD and heart problems later, and a follow-up visit is how these are caught early.Ang batong napinsala ay kailangang balikan kahit mabuti ang pakiramdam mo. Humingi ng check-up sa bato na may test ng albumin sa ihi sa loob ng 3 buwan mula sa pinsala, at mas maaga kung umuwi kang naka-dialysis, may heart failure, o ipinayo ng doktor. Ang mga nagka-AKI ay mas malamang magkaroon ng CKD at problema sa puso sa hinaharap, at sa follow-up nahuhuli nang maaga ang mga ito.Ang kidney nga nadaot kinahanglang balikan bisan maayo ang imong gibati. Pangayo og check-up sa kidney nga adunay test sa albumin sa ihi sulod sa 3 ka bulan gikan sa kadaot, ug mas sayo kung mipauli ka nga naka-dialysis, adunay heart failure, o gitambagan sa doktor. Ang mga naka-AKI mas lagmit nga makabaton og CKD ug problema sa kasingkasing sa umaabot, ug pinaagi sa follow-up kini madakpan og sayo.Ing batung mepinsala kailangan neng balikan agyang mayap ing panamdam mu. Mangayu kang check-up king batu a atin test ning albumin king imi king lub ning 3 bulan manibat king pinsala, at mas maranun nung minuli kang naka-dialysis, atin kang heart failure, o inatul ning doktor. Deng mika-AKI mas malyari lang mika-CKD at problema king pusu king daratang a panaun, at king follow-up la mararakap maranun deti.

Tests that show how your organs are getting alongMga test na nagpapakita kung paano nagkakasundo ang mga organ moMga test nga magpakita kung giunsa pagkasinabot sa imong mga organDeng test a magpakit nung makananu lang mikakasundu deng organ mu

No single test shows the whole picture. Read together, these tests show how the organs are getting along.Walang iisang test na nagpapakita ng buong larawan. Kapag binasa nang sabay-sabay, ipinapakita ng mga test na ito kung paano nagkakasundo ang mga organ.Walay usa ka test nga magpakita sa tibuok hulagway. Kung basahon nga mag-uban, kini nga mga test magpakita kung giunsa pagkasinabot sa mga organ.Alang metung a test a magpakit king mabilug a larawan. Nung basan lang misasabe, deting test papakit da nung makananu lang mikakasundu deng organ.

Six windows, each showing a test beside the organ it reports on: a blood tube, a urine cup, a blood pressure cuff and scale, a heartbeat line, red blood cells with bone marrow, and a bone with a neck gland

Each test looks at one partnership. Read together, they show how the organs are getting along.Bawat test ay tumitingin sa isang ugnayan. Kapag binasa nang sabay-sabay, ipinapakita nila kung paano nagkakasundo ang mga organ.Ang matag test motan-aw sa usa ka kalambigitan. Kung basahon nga mag-uban, magpakita sila kung giunsa pagkasinabot sa mga organ.Ing balang test lalawen ne ing metung a ugnayan. Nung basan lang misasabe, papakit da nung makananu lang mikakasundu deng organ.

eGFR
Estimated glomerular filtration rate
PTH
Parathyroid hormone

What protects several organs at onceAno ang sabay na nagpoprotekta sa ilang organUnsay dungan nga nanalipod sa pipila ka organNanu ing sabe-sabeng mamrotekta kareng pilan a organ

Because the organs are linked, caring for one often helps the others. Controlling blood pressure and blood sugar, eating less salt, staying active, not smoking and keeping your vaccines up to date protect the kidneys, heart and brain together.Dahil magkakaugnay ang mga organ, ang pag-aalaga sa isa ay kadalasang nakatutulong sa iba. Ang pagkontrol sa presyon at asukal sa dugo, pagbawas ng asin, pagiging aktibo, hindi paninigarilyo at kumpletong bakuna ay sabay na nagpoprotekta sa bato, puso at utak.Tungod kay magkadugtong ang mga organ, ang pag-atiman sa usa kasagarang makatabang sa uban. Ang pagkontrol sa presyon ug asukal sa dugo, pagkunhod sa asin, pagpabiling aktibo, dili pagpanigarilyo ug kompletong bakuna dungan nga nanalipod sa kidney, kasingkasing ug utok.Uling mikakawing la ring organ, ing pamag-alaga king metung kalambang makasaup ya kareng aliwa. Ing pamagkontrol king presyon at asukal king daya, pamagbawas asin, pamanatiling aktibu, e pamanigarilyu at kumpletung bakuna sabe-sabe dang poprotektan ing batu, pusu at utak.

Kidneys, a heart and a brain inside a green protective ring, with six habit icons pointing inward: blood pressure control, blood sugar control, less salt, staying active, no smoking and vaccines

Blood pressure, blood sugar, salt, activity, not smoking and vaccines protect several organs at once.Ang presyon, asukal sa dugo, asin, pagiging aktibo, hindi paninigarilyo at bakuna ay sabay na nagpoprotekta sa ilang organ.Ang presyon, asukal sa dugo, asin, pagka-aktibo, dili pagpanigarilyo ug bakuna dungan nga nanalipod sa pipila ka organ.Ing presyon, asukal king daya, asin, pangaaktibu, e pamanigarilyu at bakuna sabe-sabe dang poprotektan deng pilan a organ.

Some medicines were shown in large studies to protect the kidneys and the heart at the same time in people with CKD. These include medicines called SGLT2 inhibitors (such as empagliflozin or dapagliflozin) and, for people with type 2 diabetes, finerenone and semaglutide. They are among the best-proven treatments in kidney care, but they are not right for everyone. Ask your doctor whether one fits you.May mga gamot na napatunayan sa malalaking pag-aaral na sabay na nagpoprotekta sa bato at puso ng mga may CKD. Kabilang dito ang mga gamot na tinatawag na SGLT2 inhibitor (tulad ng empagliflozin o dapagliflozin) at, para sa may type 2 diabetes, ang finerenone at semaglutide. Kabilang ang mga ito sa pinakamahusay na napatunayang gamutan sa bato, pero hindi angkop sa lahat. Itanong sa doktor kung may bagay sa iyo.Adunay mga tambal nga napamatud-an sa dagkong mga pagtuon nga dungan nga nanalipod sa kidney ug kasingkasing sa mga adunay CKD. Lakip niini ang mga tambal nga gitawag og SGLT2 inhibitor (sama sa empagliflozin o dapagliflozin) ug, para sa adunay type 2 diabetes, ang finerenone ug semaglutide. Lakip kini sa labing napamatud-ang pagtambal sa kidney, apan dili angay sa tanan. Pangutan-a ang doktor kung aduna bay angay kanimo.Atin gamut a apatunayan kareng maragul a pag-aral a sabe dang poprotektan ing batu at pusu da reng atin CKD. Kayabe la keti deng gamut a awsan dang SGLT2 inhibitor (antimo ing empagliflozin o dapagliflozin) at, para kareng atin type 2 diabetes, ing finerenone at semaglutide. Kayabe la kareng pekamayap a apatunayan a pamanulu king batu, pero e la bage kareng ngan. Kutnan me ing doktor nung atin bage keka.

✅

Do thisGawin itoBuhata kiniGawan me ini

Bring every medicine and supplement to each visit. Ask before taking pain relievers such as ibuprofen, naproxen or mefenamic acid, which can reduce blood flow to the kidneys. If you are vomiting, have diarrhea or cannot drink, call your clinic and ask which medicines to pause until you recover.Dalhin ang lahat ng gamot at supplement sa bawat check-up. Magtanong muna bago uminom ng pain reliever tulad ng ibuprofen, naproxen o mefenamic acid, na puwedeng magpababa ng daloy ng dugo sa bato. Kung nagsusuka ka, nagtatae o hindi makainom, tumawag sa klinika at itanong kung aling gamot ang ihihinto muna hanggang gumaling ka.Dad-a ang tanang tambal ug supplement sa matag check-up. Pangutana una sa dili pa moinom og pain reliever sama sa ibuprofen, naproxen o mefenamic acid, nga makapaubos sa dagan sa dugo ngadto sa kidney. Kung nagsuka ka, nagkalibang o dili makainom, tawag sa klinika ug pangutana kung unsang tambal ang ihunong una hangtod maayo ka.Dalan mu ngan ing gamut at supplement king balang check-up. Mangutang ka pamu bayu ka minum pain reliever antimo ing ibuprofen, naproxen o mefenamic acid, a malyaring magpababa king agus ning daya king batu. Nung mumulua ka, magtaki o e ka makainum, maus ka king klinika at kutnan mu nung nanung gamut ing tuknangan pamu anggang mekaulu ka.

An older patient's hands emptying a woven bag of medicine boxes, blister packs and a bottle of capsules onto a clinic desk while a clinician checks a list; one blister pack is set aside with a question-mark tag

Bring every medicine and supplement to each visit, and ask before taking a pain reliever.Dalhin ang lahat ng gamot at supplement sa bawat check-up, at magtanong muna bago uminom ng pain reliever.Dad-a ang tanang tambal ug supplement sa matag check-up, ug pangutana una sa dili pa moinom og pain reliever.Dalan mu ngan ing gamut at supplement king balang check-up, at mangutang ka pamu bayu ka minum pain reliever.

🔬

Honesty about gut "detox" productsKatapatan tungkol sa mga "detox" na produkto para sa bitukaKamatuoran bahin sa mga "detox" nga produkto para sa tinaiKatutuan tungkul kareng "detox" a produktu para king bituka

Probiotics, "kidney cleanse" teas and charcoal products are sold to remove kidney toxins through the gut. In studies so far they changed some blood test numbers but have not been shown to slow kidney disease or help people live longer. Eating enough fiber from vegetables, fruits and whole grains, planned with your doctor or dietitian so your potassium stays safe, is a better place to start.Ang probiotics, "kidney cleanse" na tsaa at charcoal na produkto ay ibinebenta para alisin daw ang lason ng bato sa pamamagitan ng bituka. Sa mga pag-aaral sa ngayon, binago nila ang ilang numero sa dugo pero hindi pa napatunayang nagpapabagal ng sakit sa bato o nagpapahaba ng buhay. Mas mabuting magsimula sa sapat na fiber mula sa gulay, prutas at whole grains, na plinano kasama ang doktor o dietitian para ligtas ang potassium mo.Ang probiotics, "kidney cleanse" nga tsa ug charcoal nga produkto gibaligya aron kuno tangtangon ang hilo sa kidney pinaagi sa tinai. Sa mga pagtuon hangtod karon, giusab nila ang pipila ka numero sa dugo apan wala pa mapamatud-i nga makapahinay sa sakit sa kidney o makapataas sa kinabuhi. Mas maayong magsugod sa igong fiber gikan sa utanon, prutas ug whole grains, nga giplano uban sa doktor o dietitian aron luwas ang imong potassium.Ing probiotics, "kidney cleanse" a tsa at charcoal a produktu pisasali la ban kanu lakwan ing lasun ning batu kapamilatan ning bituka. Kareng pag-aral angga ngeni, binayu da ing pilan a numeru king daya pero e pa apatunayan a papabagalan de ing sakit king batu o papakaban de ing bie. Mas mayap magumpisa king sapat a fiber manibat king gule, prutas at whole grains, a plinanu kayabe ing doktor o dietitian ban ligtas ing potassium mu.

Questions to bring to your next visitMga tanong na dadalhin sa susunod mong check-upMga pangutana nga dad-on sa imong sunod nga check-upDeng kutang a dalan mu king tutuking check-up mu

Write your questions down before the visit. These are a good start.Isulat ang mga tanong mo bago ang check-up. Magandang panimula ang mga ito.Isulat ang imong mga pangutana sa dili pa ang check-up. Maayo kining sugdanan.Isulat mu la ring kutang mu bayu ing check-up. Mayap lang panumpisan deti.

A doctor listening to an older man and his daughter at a clinic desk; he points to a notebook of questions and she holds a folder of test results

Write your questions down and bring someone with you. A good visit is a conversation.Isulat ang mga tanong mo at magsama ng kasama. Ang mabuting check-up ay isang usapan.Isulat ang imong mga pangutana ug pagdala og kauban. Ang maayong check-up usa ka panag-istoryahanay.Isulat mu la ring kutang mu at magdala kang kayabe. Ing mayap a check-up metung yang pamisabi-sabi.

Common questionsMga karaniwang tanongKasagarang mga pangutanaDeng karaniwang kutang

My creatinine went up after my heart failure treatment. Did the water pills damage my kidneys?Tumaas ang creatinine ko pagkatapos gamutin ang heart failure ko. Nasira ba ng pampaihi ang bato ko?Misaka ang akong creatinine human tambali ang akong heart failure. Nadaot ba sa pampaihi ang akong kidney?Tinas ya ing creatinine ku kaybat deng penulu ing heart failure ku. Sinira na wari ning pampaimi ing batu ku?
Not necessarily. When extra fluid is removed, creatinine often rises a little while swelling and breathing improve. In a study of people treated with strong water pills, this small rise was not linked to signs of kidney cell injury. Your doctor judges it together with your blood pressure, urine amount and symptoms. Do not stop a medicine on your own.Hindi naman palagi. Kapag inalis ang sobrang tubig, kadalasang bahagyang tumataas ang creatinine habang gumaganda ang pamamaga at paghinga. Sa isang pag-aaral ng mga taong binigyan ng malakas na pampaihi, hindi naiugnay ang maliit na pagtaas na ito sa mga senyales ng pinsala sa selula ng bato. Tinitimbang ito ng doktor kasama ang presyon, dami ng ihi at sintomas mo. Huwag ihinto ang gamot nang sarili mo.Dili kanunay. Kung tangtangon ang sobrang tubig, kasagarang mosaka og gamay ang creatinine samtang moarang-arang ang paghubag ug pagginhawa. Sa usa ka pagtuon sa mga tawong gihatagan og kusog nga pampaihi, kining gamay nga pagsaka wala malambigit sa mga timaan sa kadaot sa selula sa kidney. Timbangon kini sa doktor uban sa imong presyon, gidaghanon sa ihi ug sintomas. Ayaw ihunong ang tambal sa imong kaugalingon.E naman parati. Nung lakwan ing sobrang danum, kalambang tataas yang ditak ing creatinine kabang sasanting ing pamagbulkas at pangisnawa. King metung a pag-aral kareng taung dininan masikan a pampaimi, iting malating pamagtas e ya mi-ugne kareng tanda ning pinsala king selula ning batu. Titimbangan ne ning doktor kayabe ing presyon mu, dakal ning imi at sintomas. E me tutuknangan ing gamut king sarili mu.
Why am I anemic if my problem is in the kidneys?Bakit ako may anemia kung sa bato ang problema ko?Ngano nga aduna koy anemia kung sa kidney ang akong problema?Bakit atin kung anemia nung king batu ing problema ku?
Healthy kidneys make erythropoietin, the hormone that tells the bone marrow to make red blood cells. In CKD less of it is made, and inflammation locks iron away where the marrow cannot use it. That is why doctors check iron tests before deciding on iron or injections.Ang malusog na bato ay gumagawa ng erythropoietin, ang hormone na nag-uutos sa bone marrow na gumawa ng pulang selula ng dugo. Sa CKD, mas kaunti ang nagagawa nito, at ikinukulong ng pamamaga ang iron sa lugar na hindi magamit ng marrow. Kaya sinusuri muna ng doktor ang iron bago magpasya sa iron o iniksyon.Ang himsog nga kidney maghimo og erythropoietin, ang hormone nga nagsugo sa bone marrow nga maghimo og pulang selula sa dugo. Sa CKD, mas gamay ang mahimo niini, ug ang panghubag (inflammation) mosirado sa iron sa dapit nga dili magamit sa marrow. Mao nga susihon una sa doktor ang iron sa dili pa modesisyon sa iron o indyeksyon.Ing masalese a batu gagawa yang erythropoietin, ing hormone a mag-utus king bone marrow a gumawa yang malutung selula ning daya. King CKD, mas ditak ing agagawa na, at ing inflammation kukulungan ne ing iron king lugal a e na agamit ning marrow. Anya susurian na pamu ning doktor ing iron bayu ya magdesisyon king iron o injection.
Can kidney disease affect my memory or mood?Puwede bang maapektuhan ng sakit sa bato ang memorya o damdamin ko?Makaapekto ba ang sakit sa kidney sa akong memorya o pagbati?Malyari neng apektuan ning sakit king batu ing memorya o panamdam ku?
It can. Retained wastes, high blood pressure, small-vessel disease, anemia, poor sleep and some medicines all play a part. Sudden confusion is an emergency. Tell your doctor about slower changes too, because several causes can be treated. Our kidney and brain guide explains more.Puwede. May papel ang naiipong dumi, mataas na presyon, sakit sa maliliit na ugat, anemia, kulang sa tulog at ilang gamot. Emergency ang biglaang pagkalito. Sabihin din sa doktor ang mabagal na pagbabago dahil may mga sanhing nagagamot. Mas detalyado ito sa aming gabay sa bato at utak.Mahimo. Adunay papel ang natigom nga hugaw, taas nga presyon, sakit sa gagmayng ugat, anemia, kulang sa katulog ug pipila ka tambal. Emergency ang kalit nga kalibog. Sultihi usab ang doktor bahin sa hinay nga kausaban kay adunay mga hinungdan nga matambalan. Mas detalyado kini sa among giya sa kidney ug utok.Malyari. Atin yang papel ing titipun a dinat, matas a presyon, sakit kareng malating uyat, anemia, kulang a tundu at pilan a gamut. Emergency ya ing biglang pamaglito. Sabyan mu namu king doktor ing banayad a pamagbayu uling atin sanhing malyaring panulunan. Mas detalyadu ya iti king giya mi king batu at utak.
If I fix my gut, will my kidneys heal?Kung aayusin ko ang bituka ko, gagaling ba ang bato ko?Kung ayuhon nako ang akong tinai, maayo ba ang akong kidney?Nung ayusan ke ing bituka ku, kumaulu ya ing batu ku?
No treatment aimed at gut bacteria has been proven to heal the kidneys or slow CKD. Eating well and avoiding constipation are worthwhile, but they add to proven treatments and do not replace them.Wala pang gamutang nakatuon sa bacteria ng bituka ang napatunayang nagpapagaling ng bato o nagpapabagal ng CKD. Mahalaga ang tamang pagkain at pag-iwas sa pagtitibi, pero dagdag lang ang mga ito sa napatunayang gamutan at hindi kapalit.Wala pay pagtambal nga nagtumong sa bacteria sa tinai ang napamatud-an nga makaayo sa kidney o makapahinay sa CKD. Bililhon ang saktong pagkaon ug paglikay sa pagkatubol, apan dugang lang kini sa napamatud-ang pagtambal ug dili puli.Ala pang pamanulu a makatutuk king bacteria ning bituka ing apatunayan a makaulu king batu o papabagalan ne ing CKD. Mayalaga ing ustung pamangan at pamag-ilag king pamagtibi, pero dagdag la mu kareng apatunayan a pamanulu at e la kapalit.
I feel fine after my hospital stay. Do I still need a kidney check?Maayos ang pakiramdam ko pagkatapos ma-ospital. Kailangan ko pa ba ng check-up sa bato?Maayo ang akong gibati human ma-ospital. Kinahanglan pa ba nako og check-up sa kidney?Mayap ing panamdam ku kaybat kung mi-ospital. Kailangan ku pa wari ing check-up king batu?
Yes. Kidney function can look recovered while protein leak or high blood pressure persists. A check within 3 months, with a urine albumin test, shows whether you need continued follow-up.Oo. Puwedeng mukhang gumaling na ang bato habang may tagas pa ng protina o mataas pa ang presyon. Ipinapakita ng check-up sa loob ng 3 buwan, na may test ng albumin sa ihi, kung kailangan mo pa ng tuloy-tuloy na follow-up.Oo. Ang kidney mahimong tan-awon nga naayo na samtang aduna pay tulo sa protina o taas pa ang presyon. Ang check-up sulod sa 3 ka bulan, nga adunay test sa albumin sa ihi, magpakita kung nagkinahanglan ka pa og padayong follow-up.Wa. Ing batu malyari yang lumto mekaulu ne kabang atin pang tulu ning protina o matas pa ing presyon. Ing check-up king lub ning 3 bulan, a atin test ning albumin king imi, papakit na nung kailangan mu pa ing tuluy-tuluy a follow-up.

The same creatinine can mean different things: find the active pathway

Interorgan crosstalk is the two-way exchange of signals between the kidney and distant organs. It travels through five channels: pressure and flow, hormones, nerves, handling of metabolites, and immune signals.4, 38 In health these loops are homeostasis. In acute kidney injury (AKI) and chronic kidney disease (CKD) the same loops amplify illness: a failing heart congests the kidney, and a failing kidney retains the volume, potassium and acid that strain the heart.

The clinical use of the concept is narrow and practical. Before acting on a creatinine, a hemoglobin or a phosphate, identify which organ pair is driving the abnormality, in which direction, and on what quality of evidence. The same creatinine rise calls for diuretics in one patient and for volume in another.

1

Name the pathway and its direction

Is the kidney the sender or the receiver? Congestion, low forward flow, a hormone loop, a retained solute, or a shared insult such as sepsis each point to a different next step.

2

Grade the evidence before acting

Many crosstalk mechanisms are proven only in animals. Act on guideline-backed and trial-backed steps; treat mechanism-only targets as research.

3

Prefer therapy that protects more than one organ

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce kidney disease progression, AKI and heart failure events in randomized trials.

Evidence labels used on this page. Each claim carries the design behind it, from guideline statements and randomized controlled trials (RCTs) down to laboratory work. Guideline a published recommendation or practice point, cited with its own grading; Human RCT a randomized trial in people; Human observational a cohort or registry, which shows association; Experimental cell or animal work; Narrative synthesis expert review; Established physiology accepted normal function.

Three kinds of evidence answer three different causal questions. Temporal sequence shows what came first. Experimental perturbation shows whether blocking a signal changes the outcome in a model. Human validation shows whether the signal operates in patients and whether acting on it helps them. Detecting a molecule in blood, or finding a spatial or transcriptional signature in tissue, does not establish its source, its engagement of the target, or benefit from treatment.4, 49

Three rising steps marked with a clock and calendar, a laboratory flask and two people, labeled timing, experiment and people

Timing, experiment and human studies answer different questions. A link between organs is proven only when it passes all three.

Five channels, one template

Every pathway on this page can be written in one template: source tissue → route or mediator → target → response → feedback. Writing it out exposes the weak link. Most disputed pathways have a well-defined mediator and target in animals but no proof in people that the mediator comes from the proposed source, or that removing it changes outcomes.

Diagram of a kidney exchanging signals with other organs along five labeled channels: pressure and flow, hormones, nerves, metabolite handling and immune signals, with a five-step strip reading source, mediator, target, response and feedback

The five channels of kidney-organ communication, and the five-step template used to describe each pathway: source tissue, route or mediator, target, response, and feedback.

RAAS
Renin-angiotensin-aldosterone system
EPO
Erythropoietin
FGF23
Fibroblast growth factor 23
PTH
Parathyroid hormone
ChannelHealthy exchangeHow disease turns it into an amplifierCertainty
Pressure and flowCardiac output and arterial pressure perfuse the kidney; venous pressure is its outflow pressure; the kidney sets extracellular volume.Raised venous pressure lowers the gradient across the kidney; low forward flow lowers filtration; retained sodium raises venous pressure further.Established physiology Human observational
HormonesThe kidney releases renin, erythropoietin and calcitriol, and responds to natriuretic peptides, aldosterone, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23).Renin-angiotensin-aldosterone system (RAAS) activation, falling erythropoietin and calcitriol, rising FGF23 and PTH.Established physiology Human observational
NervesRenal sympathetic efferents set vascular tone, renin release and sodium reabsorption; renal afferents feed back to central sympathetic outflow.Sustained sympathetic activation in heart failure and CKD.Established physiology
Metabolite handlingFiltration and tubular secretion set the body's exposure to solutes, acids and drugs made or absorbed elsewhere.Retention of gut-derived protein-bound solutes, acid and renally cleared drugs.Established physiology Human observational
Immune signalsCytokines, damage signals and immune cells move between organs.After AKI in animals, cytokine-dependent injury appears in lung, heart and brain; in sepsis the insult reaches several organs at once.Experimental

The kidney also modifies its own messages. Because many mediators are cleared by filtration or tubular secretion, a fall in glomerular filtration rate (GFR) raises their concentration even when production is unchanged. A high blood level in CKD therefore says little about where the molecule came from.4

What changes over hours, weeks and years

Time separates three states. AKI is an abrupt fall in kidney function within 7 days. Acute kidney disease (AKD) covers ongoing injury or incomplete recovery up to 90 days. Disease that persists beyond 90 days meets the time criterion for CKD.11 The acute course runs from insult to injury, then to recovery or persistent dysfunction; CKD adds slower adaptations in blood pressure, mineral metabolism, erythropoiesis and muscle.

A time axis divided at 7 days and 90 days into acute kidney injury, acute kidney disease and chronic kidney disease, with one insult sending arrows to a lung, a heart and a kidney

Acute kidney injury, acute kidney disease and chronic kidney disease are separated by time. An insult that injures several organs at once is not evidence that one organ injured another.

Calculator: Post-AKI Follow-Up Planner

Dates are handled as calendar dates. Leave a field blank if it is not documented; the planner shows unknowns as unknown.

Leave blank if not documented
Used only when onset is unknown
Defaults to today
Recorded for the summary; never derived here

Optional: creatinine change from baseline

A stable value from before the illness

Enter the AKI onset date, or the discharge date if onset is unknown.

⚕ A planning aid for clinicians. It gives no recovery designation, derived AKI stage, risk estimate, or medication instruction. Evaluate for CKD using established chronicity criteria.

Open the full calculator page for the evidence notes, references and printing.

⚠️

A shared insult is not crosstalk

Sepsis, shock and major surgery injure several organs simultaneously. When lung and kidney fail together, co-occurrence does not show that one caused the other. Sepsis-associated AKI is defined by timing (AKI within 7 days of sepsis onset), not by a proven kidney-specific mechanism.37, 63

What follows AKI. In a meta-analysis of 82 cohort studies (2,017,437 participants), AKI was associated with new or progressive CKD (hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.99 to 3.58; 17.76 versus 7.59 cases per 100 person-years), end-stage kidney disease (ESKD) (HR 4.81, 95% CI 3.04 to 7.62; 0.47 versus 0.08 per 100 person-years) and death (HR 1.80, 95% CI 1.61 to 2.02), with a gradient across AKI stages.51 In 25 cohort studies (254,408 adults), AKI was associated with cardiovascular mortality (relative risk [RR] 1.86, 95% CI 1.72 to 2.01), heart failure (RR 1.58, 95% CI 1.46 to 1.72) and myocardial infarction (RR 1.40, 95% CI 1.23 to 1.59).43 Human observational These are associations: sicker patients are more likely both to develop AKI and to die, and adjustment cannot remove that entirely.

What follows CKD. In more than one million adults, the adjusted hazard of death rose as estimated GFR (eGFR) fell: 1.2 at 45 to 59, 1.8 at 30 to 44, 3.2 at 15 to 29 and 5.9 below 15 mL/min/1.73 m², with a parallel rise in cardiovascular events.18 Human observational

Follow-up after AKI

The Kidney Disease: Improving Global Outcomes (KDIGO) 2012 AKI guideline advises evaluating patients 3 months after AKI for resolution, new onset, or worsening of pre-existing CKD (recommendation 2.3.4, Not Graded).28 Guideline A KDIGO 2026 guideline on AKI and AKD, with new recommendations on follow-up, was released as a public-review draft in 2026 and had not been published in final form when this page was reviewed; draft statements are not used here.32

What to measure is better supported than who should do the visit. In the ASSESS-AKI cohort (1,538 hospital survivors, 769 with AKI), a higher urine albumin-to-creatinine ratio (uACR) about 3 months after discharge was associated with kidney disease progression (HR 1.53 per doubling, 95% CI 1.45 to 1.62), and uACR discriminated better in those who had AKI (C statistic 0.82) than in those who had not (0.70).22 Human observational A six-variable model (age, sex, baseline creatinine, albuminuria, AKI severity, discharge creatinine) predicted advanced CKD after AKI with a C statistic of 0.81 on external validation.26 Human observational

Models of care are less certain. Early nephrology follow-up after dialysis-requiring AKI was associated with lower mortality in a propensity-matched cohort (HR 0.76, 95% CI 0.62 to 0.93).21 Human observational The randomized FUSION trial could enroll only 71 of 269 eligible patients; major adverse kidney events at 1 year were 44% with nephrologist follow-up and 43% with usual care (RR 1.02, 95% CI 0.60 to 1.73).52 Human RCT In 98 survivors of stage 3 AKI, multidisciplinary care improved blood pressure control (87.9% versus 57.5%) and lowered uACR at 12 months, with no difference in eGFR.55 Human RCT Both trials were small and measured feasibility or surrogate outcomes.

Heart and circulation: congestion, forward flow and how to read a creatinine

SourceFailing right or left heart
Route or mediatorRaised central venous pressure; low cardiac output; RAAS and sympathetic activation
TargetRenal veins, interstitium and glomerular capillaries
ResponseLower filtration gradient, sodium and water retention
FeedbackRetained volume raises venous pressure further
Two-panel mechanism figure of a heart and a kidney: on the left, low forward flow reduces arterial inflow to the kidney; on the right, raised venous pressure backs up into the renal veins and compresses the kidney from its outflow side

Two routes from a failing heart to a struggling kidney. Low forward flow reduces what arrives; venous congestion raises the pressure the kidney must drain against. Both lower filtration, and they call for different treatment.

CVP
Central venous pressure
GFR
Glomerular filtration rate
RAAS
Renin-angiotensin-aldosterone system

Physiology. Cardiac output and arterial pressure deliver blood to the glomerulus. Natriuretic peptides promote sodium excretion; RAAS and sympathetic nerves defend perfusion by retaining it. Filtration depends on the pressure difference across the kidney, so its outflow pressure matters as much as its inflow. Established physiology

Congestion and forward flow. In 145 patients with advanced decompensated heart failure managed with a pulmonary artery catheter, 40% developed worsening renal function. Those patients had higher central venous pressure (CVP) on admission (18 ± 7 versus 12 ± 6 mm Hg), and worsening was less frequent when CVP fell below 8 mm Hg; the relationship held across the range of cardiac index.39 Human observational In 137 patients with sepsis, higher CVP was associated with new or persistent AKI after adjustment for fluid balance (odds ratio [OR] 1.22, 95% CI 1.08 to 1.39), while mean arterial pressure and cardiac output did not differ.35 Human observational These single-center studies support congestion as a major driver; they do not exclude low forward flow in an individual patient.

A creatinine rise during decongestion is not automatically injury. In the ROSE-AHF trial population, treated with high-dose loop diuretics, worsening renal function occurred in 21.2% and was not associated with a rise in the tubular injury markers neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG) or kidney injury molecule 1 (KIM-1).3 Human observational In DOSE, bolus and continuous furosemide produced similar creatinine changes (0.05 versus 0.07 mg/dL, P = 0.45).17 Human RCT Read the creatinine with the interval over which it rose, blood pressure, perfusion, urine output and the trajectory of congestion.

Taxonomy. Cardiorenal syndrome is classified into five types: acute cardiorenal (1), chronic cardiorenal (2), acute renocardiac (3), chronic renocardiac (4) and secondary to a systemic condition (5).45, 47 Teach it as a vocabulary with overlap. Most patients move between types, and the label does not select a treatment.

Venous Excess Ultrasound (VExUS): a phenotype with conditional portability

Reference card: a vena cava diameter measurement, a grid of nine venous Doppler waveforms for the hepatic, portal and intrarenal veins graded normal, mild and severe, and three chips showing how severe patterns set the grade

The grade combines vena cava diameter with three venous Doppler patterns. It describes congestion; it is not a probability of kidney injury.

VExUS
Venous Excess Ultrasound
IVC
Inferior vena cava
AKI
Acute kidney injury
Calculator: VExUS Grading Worksheet

Enter what was measured. For the portal vein, either choose a category or type the pulsatility fraction; a typed percentage takes priority.

Under 2 cm = grade 0
(Vmax − Vmin) ÷ Vmax × 100; optional

Enter the IVC diameter to begin.

⚕ Documents the original VExUS grade from operator-classified findings. It gives no AKI probability and no diuretic or fluid recommendation.

Open the full calculator page for the evidence notes, references and printing.

VExUS combines inferior vena cava (IVC) diameter with hepatic, portal and intrarenal venous Doppler patterns. In the cardiac surgery derivation cohort (145 patients, 706 scans), the severe grade was associated with later AKI (HR 3.69, 95% CI 1.65 to 8.24; adjusted HR 2.82, 95% CI 1.21 to 6.55).7 Human observational In a general intensive care unit (ICU) cohort of 145 patients, admission VExUS was not associated with AKI (P = 0.136; grade 2 or higher, OR 0.50, 95% CI 0.21 to 1.17) or 28-day mortality.5 Human observational A 2026 meta-analysis of 32 studies (3,142 patients) found the same split: VExUS grade 2 or higher was associated with AKI in cardiac patients (OR 4.44, 95% CI 2.34 to 8.43; moderate certainty) and not in the critically ill (OR 1.45, 95% CI 0.70 to 2.99; very low certainty).33

Acting on the grade has not yet been shown to improve outcomes. In 140 patients with cardiorenal syndrome type 1, VExUS-guided decongestion did not improve kidney function recovery, although decongestion was achieved more often (OR 2.6).25 Human RCT An 80-patient pilot trial of ultrasound-assessed fluid tolerance in AKI showed feasibility and more early diuretic use, with no difference in AKI progression.19 Human RCT Use VExUS where pretest probability of congestion is meaningful, and read it with the bedside picture. A VExUS grading worksheet documents the grade and its limits.

Kidney to heart. AKI affects the heart through volume overload, hyperkalemia and acidemia. CKD adds hypertension, anemia, mineral and endocrine changes and vascular calcification. Established physiology

Interpreting the case

The later echocardiogram showed preserved left ventricular ejection fraction with impaired relaxation and findings consistent with elevated left-sided filling pressure. That distinction matters because ejection fraction describes how much blood the ventricle ejects, while filling pressure helps explain a different part of the hemodynamic picture. Renal venous congestion and the mechanism of the earlier intensive-care episode remain unconfirmed. Long-standing hypertension and diabetes provide shared pathways for cardiac and kidney injury. Changes in perfusion and volume are plausible additional contributors.13, 34

Teaching question. If breathlessness recurs, which findings would help you distinguish elevated filling pressure, systemic venous congestion, and poor perfusion? Compare the weight and symptom trends, jugular venous pressure, lung findings, blood pressure, and urine output with the kidney function trend.

The case itself is told in the Patients & Families tab, under “Why did my kidneys get worse when my heart was sick?”

Guidelines. The 2026 European Society of Cardiology (ESC) guideline on cardiovascular disease and CKD, written with the European Renal Association (ERA), is the first ESC guideline dedicated to this overlap and emphasizes earlier recognition of CKD through wider kidney function and urine albumin testing in people with cardiovascular disease.13 Guideline The 2026 American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA) and American Society of Nephrology (ASN) guideline is the first U.S. guideline on cardiovascular-kidney-metabolic (CKM) syndrome.41 Guideline KDIGO 2024 remains the reference for staging CKD by cause, GFR category and albuminuria category.30 Guideline Consult each document for its own recommendation classes; grading systems are not interchangeable.

One prescription, several organs: what the trials show

The strongest human evidence in this field does not come from blocking a named signal. It comes from drugs that improve kidney and cardiovascular outcomes together. These trials demonstrate clinical benefit in the populations studied. They do not prove which interorgan pathway is responsible, and a composite result does not isolate its components.

One plain tablet on a blank prescription pad with green arrows to shielded kidneys, a shielded heart and a shielded artery

Some treatments protect the kidneys and the heart together. The benefit is proven in trials; the pathway that explains it is not.

TrialPopulationOutcomeResultAbsolute effectHow to read it
EMPA-KIDNEY56 Human RCT6,609 adults with CKD (eGFR 20 to under 45, or 45 to under 90 with uACR 200 mg/g or more); median 2.0 yearsKidney disease progression or cardiovascular death432/3,304 (13.1%) vs 558/3,305 (16.9%); HR 0.72 (95% CI 0.64 to 0.82)3.8 fewer per 100; number needed to treat (NNT) about 26 over 2 yearsClinical benefit; the composite does not isolate cardiovascular death
SGLT2 inhibitor meta-analysis42 Human RCT13 trials, 90,409 participants, with and without diabetesKidney progression; AKI; cardiovascular death or heart failure hospitalizationRR 0.63 (95% CI 0.58 to 0.69); RR 0.77 (0.70 to 0.84); RR 0.77 (0.74 to 0.81)Varies with baseline riskOne class lowers kidney, AKI and heart failure events, similar with and without diabetes
FIDELITY1 Human RCT13,026 adults with type 2 diabetes and CKD; median 3.0 years (pooled FIDELIO-DKD and FIGARO-DKD)Cardiovascular composite; kidney composite12.7% vs 14.4%, HR 0.86 (95% CI 0.78 to 0.95); 5.5% vs 7.1%, HR 0.77 (0.67 to 0.88)1.7 and 1.6 fewer per 100; NNT about 59 and 63 over 3 yearsFinerenone; prespecified pooled analysis; monitor potassium
FLOW44 Human RCT3,533 adults with type 2 diabetes and CKD; median 3.4 yearsMajor kidney disease events331 vs 410 first events; HR 0.76 (95% CI 0.66 to 0.88); cardiovascular death HR 0.71 (0.56 to 0.89)Crude 18.7% vs 23.2%; about 4.5 fewer per 100Semaglutide 1.0 mg weekly; stopped early for efficacy
SELECT kidney analysis12 Human RCTAdults with overweight or obesity and cardiovascular disease, without diabetesPrespecified kidney composite including persistent macroalbuminuria1.8% vs 2.2%; HR 0.78 (95% CI 0.63 to 0.96)0.4 fewer per 100Secondary outcome; composite includes an albuminuria component
CONFIDENCE2 Human RCTAbout 800 adults with type 2 diabetes, CKD and albuminuria on a RAAS inhibitor; 180 daysChange in uACR (surrogate)Combination lowered uACR 29% more than finerenone alone and 32% more than empagliflozin aloneNot applicable (surrogate)Albuminuria is a surrogate; no kidney failure or cardiovascular outcome was tested

Absolute effects are differences in crude proportions over each trial's follow-up, calculated here from the published counts; they are not time-to-event estimates.

Lung: fluid, pressure and inflammation

SourceInjured kidney
Route or mediatorRetained salt and water; in animal models, circulating cytokines
TargetPulmonary capillaries and alveolar epithelium
ResponseHydrostatic edema; in models, increased permeability and impaired alveolar fluid clearance
FeedbackHypoxemia and positive-pressure ventilation alter renal perfusion and venous pressure
Two alveoli compared: on the left, fluid pushed in by high capillary pressure across an intact wall; on the right, protein-rich fluid leaking through a damaged wall; below, an arrow from a ventilated lung to a kidney

Fluid overload is the established route from kidney to lung. Cytokine-driven permeability is shown in animal models and is not yet demonstrated in patients.

Physiology. The lungs remove carbon dioxide within minutes; the kidneys adjust bicarbonate reabsorption and net acid excretion over hours to days. Each compensates for a primary disturbance in the other. Established physiology

Kidney to lung. The best-established route is fluid. In 618 critically ill patients with AKI, fluid overload at dialysis initiation was associated with death (adjusted OR 2.07), and patients who were fluid overloaded when creatinine peaked were less likely to recover kidney function.10 Human observational Animal models add a second route: after experimental AKI, cytokine-dependent increases in pulmonary vascular permeability and reduced alveolar fluid transport appear without volume overload.15, 53 Experimental Direct cytokine transfer from kidney to lung has not been demonstrated in patients.

Lung to kidney. In 8,029 ICU patients, AKI occurred in 44.3% of those with acute respiratory distress syndrome (ARDS) and 27.4% of those without; after adjustment, ARDS (OR 11.01, 95% CI 6.83 to 17.73) and mechanical ventilation without ARDS (OR 4.34, 95% CI 3.71 to 5.10) were each associated with AKI.14 Human observational A meta-analysis of 31 studies found invasive ventilation associated with a threefold increase in the odds of AKI (OR 3.16, 95% CI 2.32 to 4.28); tidal volume and positive end-expiratory pressure settings did not modify the risk, which the authors read as favoring a hemodynamic mechanism.59 Human observational

Practice. Separate hydrostatic edema, permeability edema and mixed pictures, and integrate respiratory status, fluid trajectory, hemodynamics and urine output. The Acute Disease Quality Initiative (ADQI) lung-kidney consensus found that lung-protective ventilation, conservative fluid management and early recognition and treatment of pulmonary infection were the only clinical recommendations supported by higher-quality evidence.27 Guideline

Liver: hepatorenal syndrome and the creatinine trap

SourceCirrhotic liver with portal hypertension
Route or mediatorSplanchnic vasodilation; systemic inflammation
TargetEffective arterial volume, then renal arterioles
ResponseRAAS, sympathetic and vasopressin activation; renal vasoconstriction; falling filtration
FeedbackSodium retention worsens ascites; infection or bleeding deepens the cycle
Mechanism figure: a scarred liver with dilated gut blood vessels on the left, a magnified kidney arteriole that has narrowed in the center, and a summary strip reading cause, bridge and consequence

In advanced cirrhosis the gut circulation dilates and the body reads this as underfilling. The vasoconstrictor systems that respond also narrow the kidney arterioles, and filtration falls.

HRS-AKI
Hepatorenal syndrome-acute kidney injury
RAAS
Renin-angiotensin-aldosterone system
GFR
Glomerular filtration rate

Physiology. Hepatic metabolism and renal excretion jointly clear circulating solutes. In advanced cirrhosis, splanchnic vasodilation lowers effective arterial filling and triggers vasoconstrictor systems that reduce renal perfusion. Inflammation, tubular injury and congestive physiology often coexist, so hepatorenal syndrome is one phenotype among several causes of AKI in cirrhosis.40

The creatinine trap. Sarcopenia lowers creatinine production, and creatinine therefore overestimates kidney function in advanced liver disease. A value that looks near normal can hide a large fall in GFR.

Diagnosis. The 2024 joint consensus of ADQI and the International Club of Ascites (ICA) defines hepatorenal syndrome-AKI (HRS-AKI) by four elements: cirrhosis with ascites; AKI that meets the consensus criteria; no improvement within 24 hours of adequate volume resuscitation when resuscitation is clinically indicated; and no strong evidence of an alternative primary cause. A routine 48-hour albumin challenge is no longer required.40 Guideline Look for infection, shock, obstruction, nephrotoxin exposure and tubular injury before and during treatment.

Treatment: benefit and harm are separate endpoints. In CONFIRM (300 adults with type 1 hepatorenal syndrome by the trial definition), verified reversal occurred in 63 of 199 (32%) with terlipressin and 17 of 101 (17%) with placebo (P = 0.006), an absolute difference of about 15 per 100 (NNT about 7). By day 90, death had occurred in 51% and 45%, and death from respiratory disorders in 11% and 2%.62 Human RCT The U.S. label reports serious or fatal respiratory failure in 14% of terlipressin-treated patients and 5% on placebo in the safety population, about 9 more per 100 (number needed to harm [NNH] about 11), and directs that oxygen saturation be assessed before treatment and that terlipressin not be started in patients with hypoxia; volume overload and advanced acute-on-chronic liver failure raise the risk.57 Terlipressin improved kidney function without a demonstrated survival benefit in this trial. Trial eligibility used an older definition; do not extend its effect size to every patient who meets the 2024 criteria. The HRS-AKI bedside guide covers dosing and monitoring.

Gut and liver: generation, processing and clearance of solutes

SourceColonic bacteria acting on dietary tryptophan and tyrosine
Route or mediatorIndole and p-cresol absorbed to the portal vein; hepatic sulfation
TargetProximal tubule secretion
ResponseIndoxyl sulfate and p-cresyl sulfate retained when secretion falls
FeedbackDiet change, drugs, intestinal edema and uremia reshape the microbiome
Three-step horizontal figure: gut bacteria turn dietary amino acids into indole and p-cresol, the liver adds a sulfate group, and the kidney tubule secretes the products into urine, with a faded kidney showing retention in chronic kidney disease

A gut-derived solute is generated by bacteria, processed by the liver and cleared by the kidney tubule. Each step is a different treatment target, and none has yet improved patient outcomes in trials.

CKD
Chronic kidney disease
IS
Indoxyl sulfate
PCS
p-Cresyl sulfate

Three steps, three different targets. A gut-derived solute has to be generated by microbes, processed by the host (the liver converts indole and p-cresol to indoxyl sulfate and p-cresyl sulfate), and cleared by the kidney, mainly by tubular secretion because both are protein bound. Impaired clearance raises exposure even if generation is unchanged. A systematic review found experimental and clinical data consistent with toxicity of both solutes, with the human data largely observational.60 Human observational Experimental

What the trials show. The hypothesis has been tested at each step, and no intervention has improved a patient-important outcome.

StudyStep targetedFindingReading
SYNERGY48 Human RCTGeneration (synbiotic), 6-week crossover, 37 randomized, eGFR 10 to 30Indoxyl sulfate −2 µmol/L (95% CI −5 to 1), not significant; p-cresyl sulfate −14 µmol/L (−27 to −2), a secondary outcome; albuminuria rose by 38 mg/24 hShort-term toxin concentrations only; primary outcome negative
EPPIC-1 and EPPIC-250 Human RCTAbsorption (oral carbon adsorbent AST-120, 9 g/day), 2,035 adultsDialysis, transplantation or creatinine doubling: HR 1.03 (95% CI 0.84 to 1.27) and 0.91 (0.74 to 1.12)The largest outcome test of lowering gut-derived toxin absorption found no benefit
Plant-dominant diet trial, 202658 Human RCTSubstrate (70% plant protein, same total protein), 36 adults, median eGFR 13, 4 weeksTrimethylamine N-oxide (TMAO) fell (−4.6 µg/mL, 95% CI −7.2 to −2.0); indoxyl sulfate and p-cresyl sulfate did not change; bicarbonate rose and PTH fellFeasible and metabolically favorable over 4 weeks; surrogate outcomes only

Practice. Keep microbiome-targeted therapy in the research column. A fiber-adequate, plant-forward diet is reasonable on general grounds, with potassium monitoring in advanced CKD. A 2025 consensus roadmap sets out what is needed next: causal models, standardized sampling, and trials with clinical endpoints.9 Narrative synthesis

Bone, parathyroid and vessels: an endocrine loop that reaches the heart

SourceOsteocytes
Route or mediatorFGF23 in blood, acting with the co-receptor α-Klotho
TargetRenal tubule; parathyroid gland
ResponsePhosphate excretion rises; calcitriol synthesis falls
FeedbackLower calcitriol and calcium absorption raise PTH; phosphate load drives more FGF23
Line-art diagram of a bone, a parathyroid gland, a kidney and a heart joined by dotted arrows: solid arrows for the established bone, parathyroid and kidney loop and a dashed arrow from bone to heart marked as experimental

The mineral loop between bone, parathyroid and kidney is established physiology (solid arrows). The arrow from bone to heart is dashed: it is supported by human association and animal experiments, not by treatment trials.

FGF23
Fibroblast growth factor 23
PTH
Parathyroid hormone

Physiology. FGF23 from bone promotes phosphate excretion through renal signaling that depends on α-Klotho, and suppresses calcitriol. PTH and vitamin D complete the loop across kidney, intestine and bone. As nephron mass falls, FGF23 rises early to maintain phosphate excretion, calcitriol falls, and PTH rises. Established physiology

Reach beyond bone. In 3,879 adults with CKD, higher FGF23 was associated with death (HR 1.5 per standard deviation of log FGF23, 95% CI 1.3 to 1.7; HR 3.0 in the highest versus lowest quartile).24 Human observational In patients starting hemodialysis, FGF23 was associated with a graded increase in mortality.20 Human observational A study combining a human CKD cohort with laboratory work found FGF23 independently associated with left ventricular hypertrophy in people, and showed that FGF23 induced hypertrophy in isolated cardiomyocytes through FGF receptor-dependent calcineurin signaling independent of Klotho, produced hypertrophy when injected into mice, and that an FGF receptor blocker attenuated hypertrophy in a rat CKD model.16 Human observational Experimental

These are two separate lines of evidence, a human association and an experimental mechanism. Neither is a treatment trial. No study has shown that lowering FGF23 improves cardiovascular outcomes, so FGF23 is not a therapeutic target or a routine test.

Practice. The KDIGO 2017 update on CKD-mineral and bone disorder (CKD-MBD) bases treatment on serial assessment of phosphate, calcium and PTH considered together (Not Graded), with alkaline phosphatase where indicated.31 Guideline Act on trends, not single values. See Novel regulators of mineral metabolism and the CKD-MBD calculator.

Bone marrow and immune system: oxygen sensing, iron traffic and inflammation

SourceRenal peritubular interstitial cells sensing oxygen
Route or mediatorErythropoietin in blood
TargetMarrow erythroid progenitors
ResponseRed cell production
FeedbackBetter oxygen delivery lowers erythropoietin; hepcidin from the liver limits iron supply
Mechanism figure: a kidney releasing erythropoietin to bone marrow that makes red cells, and a liver releasing hepcidin that locks iron inside a storage cell so less iron reaches the marrow

Two signals control red cell production in kidney disease: erythropoietin from the kidney drives it, and hepcidin from the liver restricts the iron it needs. Anemia in chronic kidney disease usually involves both.

EPO
Erythropoietin
TSAT
Transferrin saturation
CKD
Chronic kidney disease

Physiology. Renal oxygen sensing regulates erythropoietin and red cell production. Hepcidin, made in the liver and raised by inflammation and by reduced renal clearance, degrades ferroportin and traps iron in macrophages and enterocytes.6 Established physiology The anemia of CKD is therefore relative erythropoietin deficiency plus iron-restricted erythropoiesis, often with blood loss and other reversible causes on top.

Practice. Pair hemoglobin with ferritin and transferrin saturation (TSAT), and look for other causes before attributing anemia to CKD. KDIGO 2026 separates the decision to start iron from the rule for withholding it during treatment.29 Guideline

SettingIron initiation criteria (KDIGO 2026)Grade
CKD G5 on hemodialysisFerritin 500 ng/mL or less and TSAT 30% or lessRecommendation 2.1, 2D (a suggestion; very low certainty)
CKD not on dialysis, or on peritoneal dialysisFerritin under 100 ng/mL with TSAT under 40%, or ferritin 100 to under 300 ng/mL with TSAT under 25%Recommendation 2.3, 2D
Already receiving ironWithhold routine iron when ferritin is above 700 ng/mL or TSAT is 40% or more; with active systemic infection, apply the guideline's infection precaution before the numbersPractice point (ungraded)

The withholding thresholds mirror the proactive arm of PIVOTAL: in 2,141 patients on hemodialysis, proactive high-dose intravenous iron was noninferior for death or cardiovascular events (29.3% versus 32.3%; HR 0.85, 95% CI 0.73 to 1.00) and lowered the dose of erythropoiesis-stimulating agent (ESA).36 Human RCT The iron status calculator applies these criteria; Anemia management in CKD covers treatment.

Immune signaling. Systemic inflammatory signals contribute to kidney injury, and in experimental models injured kidneys release mediators that affect distant tissues.4, 37 Experimental In a patient with sepsis the organ of origin of a circulating cytokine cannot be assigned, which is why anti-cytokine strategies remain unproven for AKI.

Brain and autonomic nervous system

SourceBrainstem and hypothalamic centers
Route or mediatorRenal sympathetic efferent nerves
TargetRenal vessels, juxtaglomerular cells and tubules
ResponseVasoconstriction, renin release, sodium reabsorption
FeedbackRenal afferent nerves raise central sympathetic outflow
Line-art brain and pair of kidneys joined by two solid arrows, one down and one up, and one dashed arrow marked with a flask

Efferent and afferent renal nerves form an established loop. Inflammatory injury from kidney to brain rests on experimental evidence.

Physiology. Renal sympathetic efferents regulate vascular tone, renin and sodium handling; renal afferents influence central sympathetic activity. Established physiology Brain injury can in turn alter renal perfusion through autonomic and systemic responses.38

Encephalopathy. Severe kidney dysfunction may contribute to encephalopathy through metabolic disturbance and retained solutes. Attribution is difficult because vascular disease, renally cleared drugs, critical illness and delirium are common in the same patients. Experimental AKI studies implicate endothelial and blood-brain barrier injury and neuroinflammation; this has not been shown to be treatable in people.37 Experimental

Practice. For an acute change in mental status, work a differential diagnosis: sodium and glucose, acid-base status, drug accumulation, infection, stroke, and uremia last. Separate established metabolic complications from experimental neuroinflammation. See Kidney-brain axis: cognitive dysfunction in CKD and the 4AT delirium screen.

Skeletal muscle and metabolic organs: what creatinine really measures

SourceSkeletal muscle
Route or mediatorCreatinine from creatine turnover; myoglobin after muscle injury
TargetGlomerular filtration and tubules
ResponseSerum creatinine tracks muscle mass as well as GFR
FeedbackAcidosis, inflammation and inactivity in CKD reduce muscle further
Two people with identical kidneys: a muscular man makes a large pile of creatinine and his gauge reads higher; a frail older woman makes a small pile and her gauge reads lower

Creatinine is made by muscle. With the same kidney function, a person with less muscle has a lower creatinine, so the number can look better than the kidneys are.

Creatinine is a muscle product. Low muscle mass biases creatinine-based eGFR upward. KDIGO 2024 recommends combined creatinine and cystatin C estimation when creatinine-based eGFR is expected to be less accurate and GFR affects clinical decisions, with attention to the non-GFR determinants of both markers.30 Guideline Equations that combine the two markers were more accurate than creatinine alone against measured GFR.23 Human observational In 734 survivors of hospitalization for moderate to severe coronavirus disease 2019 (COVID-19), those with sarcopenia had lower eGFR but no more albuminuria, a reminder that muscle and creatinine-based eGFR move together for reasons that are not kidney damage.46 Human observational

Steady state matters. An eGFR equation assumes stable creatinine. During AKI or recovery, interpret the creatinine trajectory and urine output, not an eGFR value. The creatinine-cystatin C eGFR and kinetic eGFR calculators address the two situations separately.

Muscle loss in CKD. Metabolic acidosis, inflammation, inactivity, anorexia and impaired insulin signaling activate protein breakdown.61 Experimental Narrative synthesis Correcting acidosis is physiologically attractive, but in the BiCARB trial (300 older adults with CKD and low-grade acidosis) oral sodium bicarbonate did not improve physical performance or eGFR and caused more adverse events.8 Human RCT Mechanism did not translate into benefit in that population.

Muscle to kidney, acutely. Severe muscle injury releases myoglobin, which injures tubules through pigment toxicity, intratubular obstruction and vasoconstriction. Established physiology

Metabolic organs. Diabetes and adipose-derived signals alter renal hemodynamics and inflammation; the CKM framework stages this continuum.41 The shared-therapy trials above are the clinical expression of this axis.

Three cases: same numbers, different pathways

These are synthetic teaching cases. They show how the framework changes the next step; they are not treatment protocols.

Three case cards pairing the kidneys with a heart, a cirrhotic liver and bone marrow, each with a question mark and a one-line teaching point

Three teaching cases in which the same laboratory value leads to different next steps.

Case 1 · Heart failure and a rising creatinine
1
State A. After 3 days of intravenous diuretics, creatinine has risen from 1.2 to 1.5 mg/dL. Edema and dyspnea are improving, blood pressure is stable and urine output is brisk.
2
Reasoning. Pathway: heart to kidney, by congestion. The interval, the improving congestion and the preserved perfusion fit a hemodynamic change in filtration during effective decongestion, which was not associated with tubular injury markers in ROSE-AHF.3 Continue the plan and recheck.
3
State B. The same creatinine values, but with hypotension, cool extremities and falling urine output.
4
Reasoning. The pathway is now low forward flow or over-diuresis. The same number implies the opposite next step: reassess volume and perfusion, and review vasodilators and diuretic dose. The creatinine did not distinguish the two states; the bedside did.
Case 2 · Cirrhosis with ascites and oliguria
1
Creatinine rises from 0.8 to 1.2 mg/dL over 36 hours in a patient with decompensated cirrhosis, tense ascites and low muscle mass.
2
Reasoning. A creatinine of 1.2 mg/dL understates the fall in GFR in a sarcopenic patient. Review the response to clinically appropriate volume management over 24 hours, and examine for infection (including spontaneous bacterial peritonitis), shock, obstruction, nephrotoxin exposure and tubular injury.
3
Before a vasoconstrictor. Check oxygen saturation, respiratory symptoms and volume status. Respiratory failure was the main serious harm of terlipressin in CONFIRM and in the label.57, 62
Case 3 · Post-AKI follow-up with CKD anemia
1
A patient with established non-dialysis CKD returns 3 months after AKI. Hemoglobin is low, ferritin is 150 ng/mL and TSAT is 22%.
2
Kidney. Review kidney function at steady state and persistent albuminuria before applying or revising a CKD stage; staging needs chronicity.
3
Marrow. Ferritin 100 to under 300 ng/mL with TSAT under 25% meets the KDIGO 2026 iron initiation criteria for non-dialysis CKD (recommendation 2.3, 2D).29
4
What changes the reading. Active infection (apply the infection precaution first), bleeding (find the source), or existing iron treatment (the monitoring rule applies, not the initiation rule).

Calculators and decision aids

Each tool does one job and states its limits. All run in the browser, and none stores or transmits what is entered.

ToolJobScope and limitsStatus
Post-AKI follow-up plannerTurns a documented adult AKI hospitalization into a 3-month reassessment date, due status and checklistPlanning aid. No recovery label, derived stage, risk estimate or medication instruction. Dialysis at discharge overrides the routine listNew with this guide
Iron status in CKDShows whether ferritin and TSAT meet the KDIGO 2026 iron initiation criteria for the chosen modality, and the withholding rule during treatmentAdults with confirmed CKD and documented anemia. No dose or prescriptionExisting; fixtures rechecked
VExUS grading worksheetDocuments the original VExUS grade with a criteria trace and an incomplete-data stateClinician-only, for trained operators. No AKI probability or diuretic advice. Limited in cirrhosis, severe tricuspid regurgitation and ventilationNew with this guide; needs local ultrasound review before clinical use
Kidney Failure Risk EquationEstimates 2-year and 5-year probability of treated kidney failure from age, sex, eGFR and uACRAdults with stable CKD G3 to G5. KDIGO 2024 practice points use a 5-year risk of 3% to 5% for referral, and 2-year risks above 10% for multidisciplinary care and above 40% for kidney replacement therapy (KRT) preparation.30 Risk was overestimated in some non-North American cohorts until a calibration factor was applied;54 local calibration in Philippine cohorts was not found in the sources reviewedExisting
Creatinine-cystatin C eGFRCombined estimate when creatinine is less reliableSteady state onlyExisting
Fluid overload % and AKI stagingCumulative fluid balance; KDIGO AKI stageDescribe; do not predictExisting

Deferred on purpose. A hepatorenal syndrome criteria worksheet is held for hepatology review. A composite "crosstalk score" or gut toxin index is not offered: it would need a prespecified outcome, a development cohort, external validation, calibration, a plan for missing data, and evidence that its output improves decisions. The studies summarized here answer different questions in different populations and cannot be added together.

Research panel: vesicles, tracing and multi-omics

Three technologies are changing how these questions are asked. None yet changes care.

For a signal to become a treatment target it needs an identified source, a demonstrated route, target engagement in people, and a trial with patient-important outcomes. By that standard, the proven interventions in this field are still hemodynamic and metabolic, not anti-cytokine or anti-toxin.

Notes for Philippine practice

Pearls, pitfalls and the mechanism-outcome gap

💡

Pearls

Read a creatinine change with congestion, perfusion, urine output and time course. Measure uACR after AKI. Pair hemoglobin with ferritin and TSAT. Trend calcium, phosphate and PTH together. Use combined creatinine and cystatin C estimation when muscle mass is abnormal and the decision depends on GFR.

🚫

Pitfalls

Calling co-occurring organ failure "crosstalk" when a shared insult explains it. Treating a blood level as proof of source. Reporting a relative effect without the absolute one. Carrying a VExUS result from cardiac surgery into a general ICU patient. Extending a trial effect to patients who would not have been eligible. Converting one guideline grading system into another.

🔬

Mechanism is not outcome

Lowering indoxyl sulfate absorption did not slow CKD in EPPIC. Correcting low-grade acidosis did not improve function in BiCARB. FGF23 causes cardiac hypertrophy in animals, and no trial shows that lowering it helps patients. Each is a plausible mechanism that has not become a proven treatment.

Evidence review, sortable table and watchlist

Search. PubMed and guideline publishers were searched on November 21, 2026, for interorgan and organ crosstalk, cardiorenal syndrome, venous congestion and VExUS, lung-kidney interaction, hepatorenal syndrome, gut-derived uremic solutes, FGF23, anemia of CKD, post-AKI follow-up and cardiovascular-kidney-metabolic therapy. Every number on this page was checked against the PubMed abstract of the primary source, and guideline statements against the guideline or its publisher's summary. Statements in the hero Summary and the abstract are drawn only from this page.

Quantitative evidence at a glance. Select a column heading to sort.

StudyDesignYearPopulation and endpointResult
EMPA-KIDNEY56RCT20236,609 adults with CKD; kidney progression or cardiovascular death13.1% vs 16.9%; HR 0.72 (0.64 to 0.82)
ASSESS-AKI22Prospective matched cohort20201,538 hospital survivors, 769 with AKI; halving of eGFR or ESKDHR 1.53 per doubling of uACR (1.45 to 1.62); C statistic 0.82 after AKI
CONFIRM62RCT2021300 adults with type 1 hepatorenal syndrome; verified reversal32% vs 17%; respiratory failure 14% vs 5% (label)
VExUS derivation7Post hoc cohort2020145 cardiac surgery patients; AKISevere grade HR 3.69 (1.65 to 8.24)
VExUS general ICU5Prospective cohort2023145 ICU patients; AKINo association (P = 0.136)
VExUS meta-analysis33Meta-analysis202632 studies, 3,142 patients; AKICardiac OR 4.44 (2.34 to 8.43); critically ill OR 1.45 (0.70 to 2.99)
Faul and colleagues16Experimental with cohort2011CKD cohort; cardiomyocytes, mice and rats; left ventricular hypertrophyHuman association; hypertrophy after perturbation
SYNERGY48RCT (crossover)201637 adults with CKD; serum indoxyl sulfate−2 µmol/L (−5 to 1), not significant
EPPIC50RCT20152,035 adults with CKD; dialysis, transplant or creatinine doublingHR 1.03 and 0.91, no benefit
See and colleagues51Meta-analysis of cohorts20192,017,437 hospitalized adults; CKD, ESKD, death after AKIHR 2.67, 4.81, 1.80
FUSION52RCT202171 AKI survivors; major adverse kidney events at 1 year44% vs 43%; RR 1.02 (0.60 to 1.73)
PIVOTAL36RCT20192,141 adults on hemodialysis; death or cardiovascular events29.3% vs 32.3%; HR 0.85 (0.73 to 1.00)
BiCARB8RCT2020300 older adults with CKD; physical performanceNo benefit; more adverse events

What this review changed from the planning notes. The ASSESS-AKI estimate is given as published in the abstract (95% CI 1.45 to 1.62). The general ICU VExUS result is given for admission scores (P = 0.136). The FGF23 mechanism is described as FGF receptor-dependent, as the cited study reports, without naming a receptor subtype. One planned narrative review of organ crosstalk could not be verified in PubMed and is not cited. Added: the 2026 VExUS meta-analysis and two randomized trials of ultrasound-guided decongestion, the 2026 plant-dominant diet trial, EPPIC, PIVOTAL, BiCARB, the randomized post-AKI follow-up trials, long-term outcome meta-analyses, the shared-therapy trials, and the 2026 ESC and AHA/ACC/ADA/ASN guidelines.

Evidence watchlist. Refresh this page when the KDIGO AKI and AKD guideline is published in final form,32 and at each major guideline release in cardiology, hepatology and nephrology. Clinical review by nephrology is required before any local order set or pathway is built from this page.

Try the CalculatorsSubukan ang mga CalculatorSulayi ang mga CalculatorSubukan ing reng Calculator
⌬
Post-AKI Follow-Up Planner
The 3-month reassessment date after acute kidney injury (AKI), due status and a follow-up checklist.
Open →
⌬
Iron Status in CKD
Ferritin and transferrin saturation against the KDIGO 2026 iron initiation and withholding criteria.
Open →
⌬
VExUS Grading Worksheet
Venous congestion grade from IVC diameter and hepatic, portal and intrarenal Doppler patterns.
Open →
⌬
Kidney Failure Risk Equation
2-year and 5-year probability of kidney failure from age, sex, eGFR and urine albumin.
Open →
⌬
Creatinine–Cystatin C eGFR
Combined estimate for when creatinine alone is less reliable, such as low muscle mass.
Open →
⌬
CKD-MBD Calculator
Corrected calcium, calcium–phosphate product and PTH staging.
Open →
Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

ACC
American College of Cardiology.
ADA
American Diabetes Association.
ADQI
Acute Disease Quality Initiative, a consensus group in acute kidney care.
AHA
American Heart Association.
AKD
Acute kidney disease: kidney injury or incomplete recovery lasting up to 90 days.
AKI
Acute kidney injury: a fall in kidney function over hours to days.
ARDS
Acute respiratory distress syndrome.
ASN
American Society of Nephrology.
CI
Confidence interval.
CKD
Chronic kidney disease: kidney abnormality lasting more than 3 months.
CKD-MBD
Chronic kidney disease–mineral and bone disorder.
CKM
Cardiovascular-kidney-metabolic (syndrome).
CVP
Central venous pressure.
eGFR
Estimated glomerular filtration rate.
ERA
European Renal Association.
ESA
Erythropoiesis-stimulating agent.
ESC
European Society of Cardiology.
ESKD
End-stage kidney disease.
FGF23
Fibroblast growth factor 23, a bone hormone that controls phosphate.
GFR
Glomerular filtration rate.
HR
Hazard ratio.
HRS-AKI
Hepatorenal syndrome–acute kidney injury.
ICA
International Club of Ascites.
ICU
Intensive care unit.
IVC
Inferior vena cava.
KDIGO
Kidney Disease: Improving Global Outcomes.
KIM-1
Kidney injury molecule 1, a tubular injury marker.
KRT
Kidney replacement therapy (dialysis or transplantation).
NAG
N-acetyl-β-D-glucosaminidase, a tubular injury marker.
NGAL
Neutrophil gelatinase-associated lipocalin, a tubular injury marker.
NNH
Number needed to harm.
NNT
Number needed to treat.
OR
Odds ratio.
PTH
Parathyroid hormone.
RAAS
Renin-angiotensin-aldosterone system.
RCT
Randomized controlled trial.
RNA
Ribonucleic acid.
RR
Relative risk.
SGLT2
Sodium-glucose cotransporter 2.
TMAO
Trimethylamine N-oxide, a gut-derived solute.
TSAT
Transferrin saturation, a measure of iron available in blood.
uACR
Urine albumin-to-creatinine ratio.
VExUS
Venous Excess Ultrasound, a grading system for venous congestion.

Terms

Albuminuria
Albumin, a blood protein, leaking into the urine.
Ascites
Fluid collected in the abdomen, usually from liver disease.
Calcitriol
The active form of vitamin D, made in the kidney.
Cardiorenal syndrome
Heart and kidney dysfunction in which each worsens the other.
Cirrhosis
Advanced scarring of the liver.
Congestion
Blood backing up in the veins because the heart cannot move it forward.
Creatinine
Waste product of muscle, used to estimate kidney function.
p-Cresyl sulfate
A second gut-derived solute retained in CKD.
Crosstalk
Two-way signaling between organs.
Cystatin C
Blood protein used to estimate kidney function that depends less on muscle mass.
Decongestion
Removal of excess fluid, usually with diuretics.
Erythropoietin
Kidney hormone that tells the bone marrow to make red blood cells.
Ferritin
Blood test that reflects stored iron and rises with inflammation.
Finerenone
Nonsteroidal mineralocorticoid receptor antagonist used in CKD with type 2 diabetes.
Hepatorenal syndrome
Kidney failure in advanced cirrhosis caused by reduced blood flow to the kidneys.
Hepcidin
Liver hormone that locks iron in storage.
Indoxyl sulfate
Solute made from gut bacterial products and normally cleared by the kidneys.
α-Klotho
Co-receptor that lets FGF23 act on the kidney.
Sarcopenia
Loss of muscle mass and strength.
Semaglutide
Glucagon-like peptide-1 receptor agonist.
Surrogate endpoint
A measurement, such as a laboratory value, used in place of an outcome patients feel.
Synbiotic
A combination of probiotic bacteria and the fiber that feeds them.
Terlipressin
Vasoconstrictor used for hepatorenal syndrome.
Tubular secretion
Active transport of solutes from blood into urine by kidney tubule cells.
ReferencesMga SanggunianMga TinubdanReng Reperensya 63 sources
  1. Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., Bakris, G. L., & FIDELIO-DKD and FIGARO-DKD investigators. (2022). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. European Heart Journal, 43(6), 474–484. https://doi.org/10.1093/eurheartj/ehab777
  2. Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., Edfors, R., Li, N., Scheerer, M. F., Scott, C., Nangaku, M., & CONFIDENCE Investigators. (2025). Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. New England Journal of Medicine, 393(6), 533–543. https://doi.org/10.1056/NEJMoa2410659
  3. Ahmad, T., Jackson, K., Rao, V. S., Tang, W. H. W., Brisco-Bacik, M. A., Chen, H. H., Felker, G. M., Hernandez, A. F., O'Connor, C. M., Sabbisetti, V. S., Bonventre, J. V., Wilson, F. P., Coca, S. G., & Testani, J. M. (2018). Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation, 137(19), 2016–2028. https://doi.org/10.1161/CIRCULATIONAHA.117.030112
  4. Alkhansa, S., Bronstein, R., & Mallipattu, S. K. (2026). Interorgan signaling in kidney health and disease. Journal of the American Society of Nephrology. Advance online publication. https://doi.org/10.1681/ASN.0000001311
  5. Andrei, S., Bahr, P. A., Nguyen, M., Bouhemad, B., & Guinot, P. G. (2023). Prevalence of systemic venous congestion assessed by Venous Excess Ultrasound Grading System (VExUS) and association with acute kidney injury in a general ICU cohort: A prospective multicentric study. Critical Care, 27(1), Article 224. https://doi.org/10.1186/s13054-023-04524-4
  6. Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 23(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078
  7. Beaubien-Souligny, W., Rola, P., Haycock, K., Bouchard, J., Lamarche, Y., Spiegel, R., & Denault, A. Y. (2020). Quantifying systemic congestion with point-of-care ultrasound: Development of the venous excess ultrasound grading system. The Ultrasound Journal, 12(1), Article 16. https://doi.org/10.1186/s13089-020-00163-w
  8. BiCARB Study Group. (2020). Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): A pragmatic randomised, double-blind, placebo-controlled trial. BMC Medicine, 18(1), Article 91. https://doi.org/10.1186/s12916-020-01542-9
  9. Bloom, P. P., Garrett, W. S., Penniston, K. L., Winkler, M. H., Hazen, S. L., Agudelo, J., Suryavanshi, M., Babiker, A., Dodd, D., Fischbach, M. A., Huang, K. C., Huttenhower, C., Joe, B., Kalantar-Zadeh, K., Knight, R., Miller, A. W., Rabb, H., Srivastava, A., Tang, W. H. W., ... Pluznick, J. L. (2025). Microbiota and kidney disease: The road ahead. Nature Reviews Nephrology, 21(10), 702–716. https://doi.org/10.1038/s41581-025-00988-5
  10. Bouchard, J., Soroko, S. B., Chertow, G. M., Himmelfarb, J., Ikizler, T. A., Paganini, E. P., Mehta, R. L., & Program to Improve Care in Acute Renal Disease (PICARD) Study Group. (2009). Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney International, 76(4), 422–427. https://doi.org/10.1038/ki.2009.159
  11. Chawla, L. S., Bellomo, R., Bihorac, A., Goldstein, S. L., Siew, E. D., Bagshaw, S. M., Bittleman, D., Cruz, D., Endre, Z., Fitzgerald, R. L., Forni, L., Kane-Gill, S. L., Hoste, E., Koyner, J., Liu, K. D., Macedo, E., Mehta, R., Murray, P., Nadim, M., ... Acute Disease Quality Initiative Workgroup 16. (2017). Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nature Reviews Nephrology, 13(4), 241–257. https://doi.org/10.1038/nrneph.2017.2
  12. Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., Wilding, J. P. H., Mann, J. F. E., Tuttle, K. R., Idorn, T., Rathor, N., & Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine, 30(7), 2058–2066. https://doi.org/10.1038/s41591-024-03015-5
  13. Damman, K., Ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A., Gansevoort, R. T., Gavina, C., Goette, A., Gorog, D. A., Gotcheva, N. N., Kaluzna-Oleksy, M., Kelly, D. M., Korzh, O., Lees, J. S., Manfrini, O., Martens, P., Nunez, J., ... ESC Guidelines Advisory Group. (2026). 2026 ESC guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). European Heart Journal. Advance online publication. https://doi.org/10.1093/eurheartj/ehag098
  14. Darmon, M., Clec'h, C., Adrie, C., Argaud, L., Allaouchiche, B., Azoulay, E., Bouadma, L., Garrouste-Orgeas, M., Haouache, H., Schwebel, C., Goldgran-Toledano, D., Khallel, H., Dumenil, A. S., Jamali, S., Souweine, B., Zeni, F., Cohen, Y., & Timsit, J. F. (2014). Acute respiratory distress syndrome and risk of AKI among critically ill patients. Clinical Journal of the American Society of Nephrology, 9(8), 1347–1353. https://doi.org/10.2215/CJN.08300813
  15. Faubel, S., & Edelstein, C. L. (2016). Mechanisms and mediators of lung injury after acute kidney injury. Nature Reviews Nephrology, 12(1), 48–60. https://doi.org/10.1038/nrneph.2015.158
  16. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., ... Wolf, M. (2011). FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation, 121(11), 4393–4408. https://doi.org/10.1172/JCI46122
  17. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., ... NHLBI Heart Failure Clinical Research Network. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/NEJMoa1005419
  18. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C. Y. (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine, 351(13), 1296–1305. https://doi.org/10.1056/NEJMoa041031
  19. Gouin, M., Huard, K., Shen, A., Côté, J. M., Denault, A., & Beaubien-Souligny, W. (2026). A pilot randomized controlled trial of ultrasound evaluation of fluid tolerance for acute kidney injury: USE-the-FORCE-for-AKI trial. Clinical Journal of the American Society of Nephrology, 21(7), 1126–1134. https://doi.org/10.2215/CJN.0000001059
  20. Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., & Wolf, M. (2008). Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New England Journal of Medicine, 359(6), 584–592. https://doi.org/10.1056/NEJMoa0706130
  21. Harel, Z., Wald, R., Bargman, J. M., Mamdani, M., Etchells, E., Garg, A. X., Ray, J. G., Luo, J., Li, P., Quinn, R. R., Forster, A., Perl, J., & Bell, C. M. (2013). Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney International, 83(5), 901–908. https://doi.org/10.1038/ki.2012.451
  22. Hsu, C. Y., Chinchilli, V. M., Coca, S., Devarajan, P., Ghahramani, N., Go, A. S., Hsu, R. K., Ikizler, T. A., Kaufman, J., Liu, K. D., Parikh, C. R., Reeves, W. B., Wurfel, M., Zappitelli, M., Kimmel, P. L., Siew, E. D., & ASSESS-AKI Investigators. (2020). Post-acute kidney injury proteinuria and subsequent kidney disease progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study. JAMA Internal Medicine, 180(3), 402–410. https://doi.org/10.1001/jamainternmed.2019.6390
  23. Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Gutiérrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., ... Chronic Kidney Disease Epidemiology Collaboration. (2021). New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737–1749. https://doi.org/10.1056/NEJMoa2102953
  24. Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A. H., Scialla, J., Wahl, P., Gutiérrez, O. M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheimer, J., Hsu, C. Y., Lash, J., Leonard, M., Kusek, J. W., Feldman, H. I., ... Chronic Renal Insufficiency Cohort (CRIC) Study Group. (2011). Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 305(23), 2432–2439. https://doi.org/10.1001/jama.2011.826
  25. Islas-Rodríguez, J. P., Miranda-Aquino, T., Romero-González, G., Hernández-Del Rio, J., Camacho-Guerrero, J. R., Covarrubias-Villa, S., Ivey-Miranda, J. B., & Chávez-Íñiguez, J. S. (2024). Effect on kidney function recovery guiding decongestion with VExUS in patients with cardiorenal syndrome 1: A randomized control trial. Cardiorenal Medicine, 14(1), 1–11. https://doi.org/10.1159/000535641
  26. James, M. T., Pannu, N., Hemmelgarn, B. R., Austin, P. C., Tan, Z., McArthur, E., Manns, B. J., Tonelli, M., Wald, R., Quinn, R. R., Ravani, P., & Garg, A. X. (2017). Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. JAMA, 318(18), 1787–1797. https://doi.org/10.1001/jama.2017.16326
  27. Joannidis, M., Forni, L. G., Klein, S. J., Honore, P. M., Kashani, K., Ostermann, M., Prowle, J., Bagshaw, S. M., Cantaluppi, V., Darmon, M., Ding, X., Fuhrmann, V., Hoste, E., Husain-Syed, F., Lubnow, M., Maggiorini, M., Meersch, M., Murray, P. T., Ricci, Z., ... Kellum, J. A. (2020). Lung-kidney interactions in critically ill patients: Consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Medicine, 46(4), 654–672. https://doi.org/10.1007/s00134-019-05869-7
  28. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements, 2(1), 1–138. https://doi.org/10.1038/kisup.2012.1
  29. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2026). KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1S), S1–S99. https://kdigo.org/wp-content/uploads/2026/04/KDIGO-2026-Anemia-in-CKD-Guideline.pdf
  30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  31. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney International Supplements, 7(1), 1–59. https://doi.org/10.1016/j.kisu.2017.04.001
  32. Kidney Disease: Improving Global Outcomes (KDIGO). (2026). KDIGO 2026 clinical practice guideline for acute kidney injury (AKI) and acute kidney disease (AKD): Public review draft. https://kdigo.org/guidelines/acute-kidney-injury/
  33. Klompmaker, P., Opschoor, K., Dalen, J. T., de Vries, R., Balan, C., Veelo, D. P., Vlaar, A. P. J., & Tuinman, P. R. (2026). Diagnostic and prognostic value of the Venous Excess Ultrasound Grading System (VExUS): A systematic review and meta-analysis. Critical Care Medicine, 54(9), 2419–2429. https://doi.org/10.1097/CCM.0000000000007219
  34. Køber, L., Adamo, M., Ruwald, A. C., Tomasoni, D., Anderson, L. J., Andersson, C., Brugts, J. J., Chioncel, O., Donal, E., Ferdinandy, P., Jhund, P. S., Leyva, F., Lorusso, R., Madigan, M., Mullens, W., Paolillo, S., Ryan, N., Simpson, M., Thiele, H., ... ESC Guidelines Advisory Group. (2026). 2026 ESC guidelines for the management of heart failure. European Heart Journal, 47(38), 5346–5457. https://doi.org/10.1093/eurheartj/ehag100
  35. Legrand, M., Dupuis, C., Simon, C., Gayat, E., Mateo, J., Lukaszewicz, A. C., & Payen, D. (2013). Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: A retrospective observational study. Critical Care, 17(6), Article R278. https://doi.org/10.1186/cc13133
  36. Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H., Tomson, C. R. V., Wheeler, D. C., Winearls, C. G., Ford, I., & PIVOTAL Investigators and Committees. (2019). Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), 447–458. https://doi.org/10.1056/NEJMoa1810742
  37. Manca, B., Forni, L., Booke, H., Meuth, S., Koyner, J., La, A., & Zarbock, A. (2026). AKI as a systemic syndrome and its impact on other organ systems. Critical Care, 30(1). https://doi.org/10.1186/s13054-026-06252-x
  38. Mayerhöfer, T., Legrand, M., Darmon, M., & Joannidis, M. (2025). Kidney-organ interactions: Recent advances and clinical implications. Current Opinion in Critical Care, 31(6), 646–653. https://doi.org/10.1097/MCC.0000000000001327
  39. Mullens, W., Abrahams, Z., Francis, G. S., Sokos, G., Taylor, D. O., Starling, R. C., Young, J. B., & Tang, W. H. W. (2009). Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. Journal of the American College of Cardiology, 53(7), 589–596. https://doi.org/10.1016/j.jacc.2008.05.068
  40. Nadim, M. K., Kellum, J. A., Forni, L., Francoz, C., Asrani, S. K., Ostermann, M., Allegretti, A. S., Neyra, J. A., Olson, J. C., Piano, S., VanWagner, L. B., Verna, E. C., Akcan-Arikan, A., Angeli, P., Belcher, J. M., Biggins, S. W., Deep, A., Garcia-Tsao, G., Genyk, Y. S., ... Durand, F. (2024). Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. Journal of Hepatology, 81(1), 163–183. https://doi.org/10.1016/j.jhep.2024.03.031
  41. Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., de Boer, I. H., Ellison, D. H., Evangelista, L. S., Heffron, S. P., Kazi, D. S., Kulshreshtha, A., Lingvay, I., Low Wang, C. C., Mercado, C. A., ... Virani, S. S. (2026). 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 154(4), e50–e158. https://doi.org/10.1161/CIR.0000000000001453
  42. Nuffield Department of Population Health Renal Studies Group & SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium (SMART-C). (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400(10365), 1788–1801. https://doi.org/10.1016/S0140-6736(22)02074-8
  43. Odutayo, A., Wong, C. X., Farkouh, M., Altman, D. G., Hopewell, S., Emdin, C. A., & Hunn, B. H. (2017). AKI and long-term risk for cardiovascular events and mortality. Journal of the American Society of Nephrology, 28(1), 377–387. https://doi.org/10.1681/ASN.2016010105
  44. Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., Pratley, R., & FLOW Trial Committees and Investigators. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
  45. Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., Ronco, C., Tang, W. H. W., McCullough, P. A., & American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. (2019). Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation, 139(16), e840–e878. https://doi.org/10.1161/CIR.0000000000000664
  46. Ribeiro, H. S., Mondini, D. R., Santa-Catharina, G. P., Marçal, L., Antonângelo, L., Yu, L., Zanetta, D. M. T., Battistella, L. R., Busatto, G. F., Carvalho, C. R. R., Burdmann, E. A., & HCFMUSP COVID-19 Study Group. (2026). Skeletal muscle-kidney crosstalk in a cohort of critical illness survivors. PLOS ONE, 21(1), Article e0339795. https://doi.org/10.1371/journal.pone.0339795
  47. Ronco, C., Haapio, M., House, A. A., Anavekar, N., & Bellomo, R. (2008). Cardiorenal syndrome. Journal of the American College of Cardiology, 52(19), 1527–1539. https://doi.org/10.1016/j.jacc.2008.07.051
  48. Rossi, M., Johnson, D. W., Morrison, M., Pascoe, E. M., Coombes, J. S., Forbes, J. M., Szeto, C. C., McWhinney, B. C., Ungerer, J. P. J., & Campbell, K. L. (2016). Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A randomized trial. Clinical Journal of the American Society of Nephrology, 11(2), 223–231. https://doi.org/10.2215/CJN.05240515
  49. Scheidereit, E. M., Mavrommatis, L., & Kuppe, C. (2026). Cell–cell crosstalk in kidney health and disease. Nature Reviews Nephrology, 22(3), 199–214. https://doi.org/10.1038/s41581-025-01025-1
  50. Schulman, G., Berl, T., Beck, G. J., Remuzzi, G., Ritz, E., Arita, K., Kato, A., & Shimizu, M. (2015). Randomized placebo-controlled EPPIC trials of AST-120 in CKD. Journal of the American Society of Nephrology, 26(7), 1732–1746. https://doi.org/10.1681/ASN.2014010042
  51. See, E. J., Jayasinghe, K., Glassford, N., Bailey, M., Johnson, D. W., Polkinghorne, K. R., Toussaint, N. D., & Bellomo, R. (2019). Long-term risk of adverse outcomes after acute kidney injury: A systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney International, 95(1), 160–172. https://doi.org/10.1016/j.kint.2018.08.036
  52. Silver, S. A., Adhikari, N. K., Bell, C. M., Chan, C. T., Harel, Z., Kitchlu, A., Meraz-Muñoz, A., Norman, P. A., Perez, A., Zahirieh, A., & Wald, R. (2021). Nephrologist follow-up versus usual care after an acute kidney injury hospitalization (FUSION): A randomized controlled trial. Clinical Journal of the American Society of Nephrology, 16(7), 1005–1014. https://doi.org/10.2215/CJN.17331120
  53. Sullivan, K. M., Liu, K. D., & Matthay, M. A. (2025). Organ crosstalk during injury: Mechanisms of lung-kidney interaction in critical illness. Comprehensive Physiology, 15(6), Article e70069. https://doi.org/10.1002/cph4.70069
  54. Tangri, N., Grams, M. E., Levey, A. S., Coresh, J., Appel, L. J., Astor, B. C., Chodick, G., Collins, A. J., Djurdjev, O., Elley, C. R., Evans, M., Garg, A. X., Hallan, S. I., Inker, L. A., Ito, S., Jee, S. H., Kovesdy, C. P., Kronenberg, F., Heerspink, H. J., ... CKD Prognosis Consortium. (2016). Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA, 315(2), 164–174. https://doi.org/10.1001/jama.2015.18202
  55. Thanapongsatorn, P., Chaikomon, K., Lumlertgul, N., Yimsangyad, K., Leewongworasingh, A., Kulvichit, W., Sirivongrangson, P., Peerapornratana, S., Chaijamorn, W., Avihingsanon, Y., & Srisawat, N. (2021). Comprehensive versus standard care in post-severe acute kidney injury survivors, a randomized controlled trial. Critical Care, 25(1), Article 322. https://doi.org/10.1186/s13054-021-03747-7
  56. The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Staplin, N., Wanner, C., Green, J. B., Hauske, S. J., Emberson, J. R., Preiss, D., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Hill, M., Stevens, W., Wallendszus, K., Brenner, S., Cheung, A. K., Liu, Z. H., ... Haynes, R. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233
  57. U.S. Food and Drug Administration (FDA). (2026). TERLIVAZ (terlipressin) for injection, for intravenous use: Full prescribing information (NDA 022231, revised 2026). Mallinckrodt Hospital Products. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022231s004lbl.pdf
  58. Uwatoko, R., Sakaguchi, Y., Oka, T., Doi, Y., Kawano, Y., Kadono, H., Fukuda, S., Yamamoto, R., Matsui, I., Mizui, M., Kaimori, J. Y., & Isaka, Y. (2026). Normoproteic plant-dominant protein diets, uremic toxins, and gut microbiota in patients with advanced CKD: A randomized controlled trial. American Journal of Kidney Diseases, 88(6), 948–958.e1. https://doi.org/10.1053/j.ajkd.2026.07.008
  59. van den Akker, J. P., Egal, M., & Groeneveld, A. B. (2013). Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: A systematic review and meta-analysis. Critical Care, 17(3), Article R98. https://doi.org/10.1186/cc12743
  60. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V., & Glorieux, G. (2014). The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review. Journal of the American Society of Nephrology, 25(9), 1897–1907. https://doi.org/10.1681/ASN.2013101062
  61. Wang, X. H., & Mitch, W. E. (2014). Mechanisms of muscle wasting in chronic kidney disease. Nature Reviews Nephrology, 10(9), 504–516. https://doi.org/10.1038/nrneph.2014.112
  62. Wong, F., Pappas, S. C., Curry, M. P., Reddy, K. R., Rubin, R. A., Porayko, M. K., Gonzalez, S. A., Mumtaz, K., Lim, N., Simonetto, D. A., Sharma, P., Sanyal, A. J., Mayo, M. J., Frederick, R. T., Escalante, S., Jamil, K., & CONFIRM Study Investigators. (2021). Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. New England Journal of Medicine, 384(9), 818–828. https://doi.org/10.1056/NEJMoa2008290
  63. Zarbock, A., Nadim, M. K., Pickkers, P., Gomez, H., Bell, S., Joannidis, M., Kashani, K., Koyner, J. L., Pannu, N., Meersch, M., Reis, T., Rimmelé, T., Bagshaw, S. M., Bellomo, R., Cantaluppi, V., Deep, A., De Rosa, S., Perez-Fernandez, X., Husain-Syed, F., ... Forni, L. G. (2023). Sepsis-associated acute kidney injury: Consensus report of the 28th Acute Disease Quality Initiative workgroup. Nature Reviews Nephrology, 19(6), 401–417. https://doi.org/10.1038/s41581-023-00683-3
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info